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Abstract 
A recent analysis using family history weighting and co-observation classification modeling indicated that 
BRCA1 c.594-2A>C (IVS9-2A>C), previously described to cause exon 10 skipping (a truncating 
alteration), displays characteristics inconsistent with those of a high risk pathogenic BRCA1 variant. We 
used large-scale genetic and clinical resources from the ENIGMA, CIMBA and BCAC consortia to assess 
pathogenicity of c.594-2A>C. The combined odds for causality considering case-control, segregation, and 
breast tumor pathology information was 3.23x10
-8
. Our data indicate that c.594-2A>C is always in cis 
with c.641A>G. 
The spliceogenic effect of c.[594-2A>C;641A>G] was characterized using RNA analysis of human 
samples and splicing minigenes. As expected, c.[594-2A>C; 641A>G] caused exon 10 skipping, albeit 
not due to c.594-2A>C impairing the acceptor site but rather by c.641A>G modifying exon 10 splicing 
regulatory element(s). Multiple blood-based RNA assays indicated that the variant allele did not produce 
detectable levels of full-length transcripts, with a per allele BRCA1 expression profile comprised of ≈70-
80% truncating transcripts, and ≈20-30% of in-frame 9,10 transcripts predicted to encode a BRCA1 
protein with tumor suppression function. 
We confirm that BRCA1c.[594-2A>C;641A>G] should not be considered a high-risk pathogenic variant. 
Importantly, results from our detailed mRNA analysis suggest that BRCA-associated cancer risk is likely 
not markedly increased for individuals who carry a truncating variant in BRCA1 exons 9 or 10, or any 
other BRCA1 allele that permits 20-30% of tumor suppressor function. More generally, our findings 
highlight the importance of assessing naturally occurring alternative splicing for clinical evaluation of 
variants in disease-causing genes. 
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Introduction 
Sequence variants that alter the highly conserved intronic dinucleotides at splice donor and acceptor sites 
of high-risk disease predisposition genes are often assumed to be pathogenic, due to their high likelihood 
to alter RNA splicing. Although such variants will almost certainly lead to disruption of normal splicing 
patterns, the exact nature of the resulting alternate splicing patterns cannot be reliably predicted.  Indeed, 
a standardized classification scheme recently developed for mismatch repair gene variants through 
consensus across multiple international sites (1) proposes that mRNA assay and/or clinical data are 
necessary to upgrade dinucleotide donor and acceptor variant classification from “likely pathogenic” to 
“pathogenic”.  
The dinucleotide acceptor site variant BRCA1 c.594-2A>C (also known as IVS9-2A>C) has recently been 
reported associated with clinical characteristics inconsistent with a high risk of cancer expected for a 
pathogenic BRCA1 variant (2). Previous RNA analyses of carriers of BRCA1 c.594-2A>C indicate that 
this variant is associated with an aberrant mRNA profile (3, 4), including production of exon 10 deleted 
out-of-frame transcripts. These observations indicate that the relationship between splicing aberrations 
and increased risk is not straightforward, and pose the question of which measures of mRNA transcript 
dysregulation best reflect variant pathogenicity, considering recommendations already published by the 
ENIGMA Splicing Working Group (5).  We undertook a study to assess level of risk associated with 
BRCA1 c.594-2A>C using segregation and large-scale case-control analysis, and detailed mRNA analyses 
correlating genotype with aberrant mRNA profiles.  
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Results 
Genetic studies 
Characteristics of BRCA1 c.594-2A>C variant carriers identified in BCAC, CIMBA, and ENIGMA are 
detailed in Supplementary Tables 1 and 2.  
BRCA1 c.594-2A>C (rs80358033) was identified in 7/24,605 invasive breast cancer cases and 9/25,836 
controls, when including only the 11 studies with at least one observation (Supplementary Table 1). 
Standard case-control analysis yielded an odds ratio (OR) of 0.82 (95% CI 0.26-2.47), which was little 
different after adjustment for principle components (OR 0.83, 95% CI 0.41-2.24).  However, some studies 
indicated that they had performed BRCA1/2 mutation screening of cases and may have excluded cases 
with pathogenic variants.  Since BRCA1 c.594-2A>C has generally been assumed to be pathogenic on the 
basis of its location at a splice acceptor site, this could create a bias due to preferential exclusion of c.594-
2A>C carriers cases but not controls. After exclusion of four studies that did such genetic testing, we 
were left with 5/20,992 cases and 6/22,332 controls that carried the c.594-2A>C variant (See 
Supplementary Table 1), yielding a revised OR of 0.87 (95% CI 0.26-2.86) after adjustment for principle 
components.  The odds for causality based on carrier frequency and ages at diagnosis/interview in these 
cases and controls was 7.3 x 10
-5
 (equating to an odds against pathogenicity of 13770:1). The case-control 
findings demonstrate that the BRCA1 c.594-2A>C variant is clearly not associated with a high risk of 
breast cancer, and is unlikely to be associated with even a moderate (~3-5-fold) risk of breast cancer. 
There were 15 BRCA1 c.594-2A>C carrier individuals from 13 families identified in the CIMBA dataset 
through genotyping with the iCOGS array. It was confirmed with the submitting sites that none of these 
individuals carried another pathogenic variant in BRCA1, and that 8 of these families overlapped with 
those identified via ENIGMA while the proband for another family was also recruited into BCAC. 
Overall, information for segregation analysis was available for 14 probands from ENIGMA/CIMBA 
(Supplementary Table 1), and breast tumor pathology information for 32 cases from ENIGMA, CIMBA 
9 
 
or BCAC (Supplementary Tables 1 and 2). The combined odds for causality based on segregation 
analysis, assuming BRCA1 age-specific risks of breast and ovarian cancer as estimated in the large study 
of Antoniou et al (6), was 0.10 (ranging from 0.02 to 6.85 for individual families). The breast tumor 
pathology features of variant carriers were not consistent with those found commonly for high-risk 
BRCA1 pathogenic variant carriers. The majority of tumors were ER positive (25/32), and the odds for 
causality based on pathology information was 4.98x10
-6
 (200994:1 against causality). 
After contacting the submitting centres and through re-investigation of original genetic test results, the 
BRCA1 exonic variant rs55680408 (c.641A>G, p.Asp214Gly) was confirmed to be present in all 
ENIGMA/CIMBA c.594-2A>C families included in the final analysis, and another 13 c.594-2A>C 
carriers identified by Ambry Genetics that were excluded from analysis due to lack of relevant clinical 
information. Specifically, review of genetic testing data by Ambry Genetics identified a total of 20 
carriers of BRCA1 c.[594-2A>C; 641A>G] from >213,000 tests, including two siblings and a mother-
daughter pair; there was clear evidence that the alleles were in cis from next generation sequencing reads, 
and neither allele was observed alone in 2636 unrelated parent exomes. Further, all carrier individuals 
from BCAC were shown to share the same BRCA1 haplotype (data not shown). Based on the haplotype 
and genotype information, it was assumed that all BRCA1 c.594-2A>C carriers in the BCAC dataset were 
also carriers of c.641A>G (p.Asp214Gly). Considering case-control, segregation and pathology 
information, the combined odds for causality was 3.61x10
-11
 (i.e. 2.77x10
10
:1 against causality). These 
results indicate that individuals carrying BRCA1c.[594-2A>C; 641A>G] (Supplemental Figure 1A) 
should be counselled as not having a high risk of BRCA1-associated disease. 
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Splicing studies 
 
Comprehensive characterization of BRCA1 alternative splicing landscape in c.[594-2A>C; 641 A>G] 
carriers by capillary electrophoresis and high throughput RNA sequencing (RNAseq).  
 
To search for a plausible biological mechanism explaining the lack of evidence for an increased cancer 
risk in BRCA1 c.[594-2A>C; 641A>G] carriers, we first performed a comprehensive characterization of 
the BRCA1 alternative splicing landscape in the vicinity of exon 10.With this aim, we performed a series 
of capillary electrophoresis analyses on RNAs obtained from lymphoblastoid cell lines (LCLs) (see 
methods). We have shown previously that this approach is highly sensitive, allowing comprehensive 
identification, characterization, and semi-quantification of alternative splicing (4, 7). Experiments 
performed with two combinations of forward and reverse primers located in exons 8 and 11detected up to 
five different alternative splicing events both in LCLs from one c.[594-2A>C; 641 A>G] carrier (Carrier 
1) and healthy controls (Figure 1), including 3 in-frame (full-length (FL), 9,10, and ▼10p), and two out-
of-frame  (9 and 10). All but ▼10p (r.594-21_594-1ins) have been described previously as naturally 
occurring BRCA1 alternative splicing events in control samples (7). No c.[594-2A>C; 641A>G] specific 
events were identified. Overall, experiments conducted in the presence of puromycin (Puro+ experiments 
in Figure 1 and Supplemental Figure 1) indicated that 9,10 splicing fraction (9,10SF) is similar in 
Carrier 1 and Controls (≈29%), 10SF is considerably higher (≈38% vs. ≈1%), and FLSF much lower 
(≈31% vs. ≈66%). 9SF (<3%) and ▼10pSF (<1%)were rather minor alternative splicing events in all 
tested samples. As expected, Puro- experiments measured higher 9,10SF in Carrier 1 than in Controls 
(Figure 1A and Supplemental Figure 1) due to a drop in 10SF, probably reflecting nonsense mediated 
decay (NMD) degradation of out-of-frame 10 transcripts. 
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Overall, findings were confirmed by comparable experiments performed by other contributing centers 
(Supplemental Figure 2), assaying up to eight individual variant allele carriers identified in four unrelated 
families and 3 different types of samples (LCLs, Leukocytes (LEUs), and fresh whole blood); there was 
similar 9,10SF in Carriers and Controls (range 20-30% depending on specific protocols and/or sample 
used for experiments), and a significant increase of 10SF (with corresponding decrease of FLSF) in 
Carriers. Complementary analyses performed in the subpopulation of BRCA111q transcripts were 
coincident, with similar (9,10+11q)SF  in Carriers and Controls, and a significant increase of  
(10+11q)SF (with corresponding decrease of 11qSF) in Carriers (Supplemental Figure 2C). 
Incidentally, our data supports ▼10p as a naturally occurring BRCA1 alternative splicing event not 
previously reported, probably due to its very low SF. Capillary electrophoresis findings (in particular the 
lack of variant allele specific transcripts, and the detection of ▼10p in Controls) were confirmed by 
RNA-seq experiments (Supplemental Figure 3). 
 
 
Quantitative analyses combined with alternative splicing event specific biallelic expression analyses 
confirms that c.[594-2A>C; 641A>G] modifies the BRCA1 alternative splicing landscape, but not the 
overall BRCA1 expression level.  
 
The comprehensive analysis of the BRCA1 alternative splicing landscape described above did not provide 
an obvious explanation for why c.[594-2A>C; 641A>G] carriers do not display features of a standard 
pathogenic BRCA1 variant. Yet, the absence of carrier-specific transcripts prompted us to speculate that it 
is perhaps the actual level of naturally occurring in-frame transcripts in variant allele carriers that may 
explain the genetic findings, in particular levels of FL and 9,10 transcripts given that▼10p transcript 
levels were very low. Since capillary electrophoresis is a semi-quantitative approach, we decided to 
perform further analyses with quantitative PCR (qPCR) and digital PCR (dPCR) that, overall, confirmed 
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capillary electrophoresis findings (Figure 2). qPCR absolute quantification of individual alternative 
splicing events in Carrier 1 estimated for 9,10SF a value of 19%±0.9, in the upper-limit of Controls 
(ranging from 4% to 17%)(Figure 2A, left), together with an obvious reduction of FL transcripts (Figure 
2A, right). In addition to 9,10, three other naturally occurring in-frame alternative splicing events 
involving exon 10 and/or nearby exon 11 have been described, namely 9_11, 11, and 11q (7). We 
used qPCR absolute quantification to estimate the SF of these alternative splicing events, detecting an 
increase of (9,10+11q)SF in Carrier 1 (9%±0.8) if compared with Controls (average of 7%). No 
differences were observed with regard to 11SF and 9_11SF (Supplemental Figure 4). Similarly, dPCR 
analyses (Figure 2B) revealed a modest increase of 9,10SF in Carrier 1 (24%±0.9) if compared with 
Controls (average of 17%), together with a 50% reduction of FL
SF 
that is fully compatible with lack of FL 
transcripts arising from the variant allele.  
 
Alternative splicing event specific reverse transcription and PCR amplification (RT-PCR) sequencing 
experiments (Supplemental Figure 5) performed in carriers 3 to 5 (from one Dutch family) confirmed that 
9,10 expression is biallelic, whereas 10 expression is essentially monoallelic (arising from the variant 
allele). Neither qPCR absolute quantification (Supplemental Figure 4A), nor biallelic expression analysis 
(Supplemental Figure 5B) suggested higher overall BRCA1expression level in c.[594-2A>C; 641A>G] 
carriers. Yet, to further exclude this possibility we performed dPCR analyses of BRCA19,10 and FL 
expression relative to BRCA2 (Supplemental Figure 6). The data indicated that 9,10 relative expression 
level is similar in LCLs from Carrier 1 and Controls, while FL expression level shows a 50% reduction, 
again supporting that the variant allele is not producing FL transcripts.   
 
Taken together, capillary electrophoresis analyses of RT-PCR products, RNAseq, qPCR, dPCR and 
alternative splicing event specific sequencing experiments supported a model in which the variant allele 
does not produce novel BRCA1 transcripts, nor increases overall BRCA1expression level, but rather 
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substitutes FL transcripts (containing exons 9 and 10) with out-of-frame 10 transcripts, such that the 
contribution of in-frame 9,10 transcripts to the overall expression level is similar or slightly higher (see 
Figure 2, Supplemental Figure 2) to that observed in wild-type (WT) alleles. Of note, according to our 
data the overall model is also probably true in the subset of BRCA111q transcripts (see Supplemental 
Figures 2C and 4B). According to this model, BRCA19 (out-of-frame) and BRCA1 ▼10p (in-frame) 
contribution to the overall expression level are very low both in variant and WT alleles (see Figure 2B and 
2C), and hence irrelevant to explain the lack of risk observed in variant allele carriers.  
 
 
Splicing reporter minigene analyses reveal that c.641A>G is causing exon 10 skipping in c.[594-2A>C; 
641 A>G] carriers. 
We also performed minigene assay experiments to dissect the contribution of the individual variants 
c.594-2A>C and c.641A>G to the splicing pattern observed in variant allele carriers. Experiments were 
performed with two minigene assays (pCAS2-BRCA1-Exon10, and pB1). A schematic representation of 
these reporter minigenes is shown in Figure 3. pCAS2-BRCA1-Exon10 and pB1 experiments performed 
in HeLa cells, as well as pB1 experiments performed in breast (MCF7 and HBL100) and ovarian 
(IGROV-1) cell lines, revealed that both c.594-2A>C and c.641A>G impair normal exon 10 splicing, 
albeit with different outcomes (Figure 3). pCAS2-BRCA1-Exon10 c.594-2A>C and pB1 c.594-2A>C 
predominantly produced▼10p transcripts, but also a minor amount of 10 transcripts (Figure 3A), a 
finding confirming previous pSPL3-BRCA1-Exon10 experiments performed in COS-7 cells (8). By 
contrast, pCAS2-BRCA1-Exon10 c.641A>G and pB1 c.641A>G mostly produced 10 but no 
detectable▼10p. The finding that c.641A>G causes exon 10 skipping albeit being located outside the 
splice site, suggests that this variant disturbs the regulation of exon 10 splicing, probably by destroying 
splicing enhancer elements and/or by creating splicing silencer elements, a hypothesis supported by an in 
silico analysis based on ESRseq scores (Supplemental Figure 7A). The presence of regulatory 
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mechanisms underlying BRCA1 exon 10 splicing was further supported by small interfering RNA 
(siRNA) experiments performed in MDA-MB231 cells showing that endogenous BRCA1 depends on 
Tra2- for exon 10 inclusion (Supplemental Figure 7B). Double mutant pCAS2-BRCA1-Exon10 c.[594-
2A>C; 641 A>G] and pB1 c.[594-2A>C; 641 A>G] experiments mimicking the variant allele observed in 
vivo produced detectable levels of both 10 and ▼10p, with 10 being the predominant outcome in all 
cell lines tested (Figure 3).  
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Discussion 
In the present study we have demonstrated that c.[594-2A>C; 641A>G] carriers (but not necessarily 
carriers of a potential BRCA1 allele in which c.594-2A>C is not linked to c.641A>G) should not be 
considered at high-risk of developing BRCA1-associated cancers. The finding is remarkable, since the 
variant allele causes exon 10 skipping, a frame-shift alteration. In addition, we propose a plausible 
biological mechanism underlying the finding, the so-called BRCA1 9,10 rescue model, and we show the 
relevance of the findings for developing disease gene variant classification algorithms.  
 
The first study addressing the spliceogenic impact of BRCA1c.594-2A>C demonstrated an association 
with exon 10 skipping (3), supporting the initial pathogenic classification by Myriad Genetics (2). Here 
we confirm exon 10 skipping in c.594-2A>C carriers, and we show that contrary to expectations this 
splicing alteration is not driven by c.594-2A>C, but rather by the linked variant c.641A>G. Further, we 
show that the variant allele does not produce full-length (FL) transcripts, nor other in-frame transcripts 
apart from normal levels of 9,10 and residual levels of ▼10p transcripts. These findings lead us to 
conclude that 9,10 transcripts arising from the variant allele confer sufficient tumor suppressor activity 
in vivo  to compensate for the lack of FL transcripts.  To be more precise, the combined genetic and 
splicing data lead us to formulate a 9,10 rescue model in which BRCA1 alleles with an associated 
9,10SF of ≈20%-30% (as measured in blood related samples) confer tumor suppressor haplosufficiency 
(Figure 4). The actual value is probably closer to 20% than to 30% (according both to qPCR and dPCR 
estimations in Carrier 1, and to capillary electrophoresis estimations in Carriers 2 to 8), but at any rate is 
very similar to that observed in control samples. The finding that 9,10 is a predominant alternative 
splicing event not only in blood derived samples but also in clinically relevant tissues such as breast and 
ovary (Supplemental Figure 8) is critical to support our rescue model for both breast and ovarian cancer. 
Indeed, family history of breast and/or ovarian cancer is a key criterion for genetic testing for most 
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participating ENIGMA and CIMBA sites, and segregation analysis modelled both breast and ovarian 
cancer risk, providing  no indication that BRCA1 c.594-2A>C (IVS9-2A>C) could be associated with 
increased ovarian cancer risk only. Further, similar to our findings reported for breast cancer, case-control 
data from a parallel study by the Ovarian Cancer Association Consortium does not support an association 
with ovarian cancer risk, with BRCA1 c.594-2A>C identified in 2/16,121 cases and 4/26,167 controls 
(OCAC, unpublished data). Note that the BRCA1 9,10 rescue model predicts lack of breast and ovarian 
cancer risk not only for BRCA1 variants causing exon 10 skipping (or exon 9 skipping), but to any loss-
of-function mutation in exons 9 or 10 (nonsense or frame shift mutations), provided that the mutant allele 
produces normal levels of 9,10 transcripts (Figure 4).  
Evidently, the BRCA1 9,10 rescue model presumes that 9,10 transcripts encode a protein isoform 
(BRCA1
p.Gly183_Lys223del
) that has tumor suppressor activity. To our knowledge, this BRCA1 isoform 
(lacking only 41 out of 1863 amino acid residues) has not been detected in vivo, nor functionally 
characterized in vitro, but tumor suppressor activity is fully compatible with structural considerations: 1) 
the 41 missing residues are unlikely to affect protein folding, since they are embedded in an intrinsically 
disordered protein region spanning amino acids 170-1649 (9);  2) BRCA1
Gly183_Lys223del 
includes all known 
functional domains/residues critical for tumor suppression, including the RING domain (spanning amino 
acids 2-103) that mediates binding to BARD1, an obligated heterodimer partner in vivo (10). 
Interestingly, BRCA1
p.Gly183_Lys223del 
lacks some residues critical for E3 ligase activity (11), a BRCA1 
function that appears to be dispensable for tumor suppression (12, 13). Yet, the most compelling 
argument supporting BRCA1
p.Gly183_Lys223del
 tumor suppressor activity stems from combined genetic and 
splicing analyses of BRCA1 c.591C>T (rs1799965). This variant, also not associated with the high risk of 
cancer expected for a pathogenic BRCA1 variant (current odds for causality of 8.50x10
-16 
based on 
segregation and pathology information, ENIGMA unpublished data), expresses mostly 9,10 transcripts, 
a significant proportion of out-of-frame 9 transcripts, and very few FL transcripts (14), strongly pointing 
to BRCA1
p.Gly183_Lys223del
 as a protein with tumor suppressor function. As far as we know, the only cancer 
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predisposition gene for which a similar alternative splicing rescue model has been proposed is the tumor 
suppressor adenomatous poliposis coli (APC) gene, albeit in this case loss of function variants in the 
alternatively spliced region of APC exon 9 are not associated with lack of risk, but with a milder 
phenotype, termed attenuated familial adenomatous polyposis(15).  
The BRCA19,10 rescue model highlights the often neglected relevance of naturally occurring alternative 
splicing in the clinical arena, and has obvious implications for variant classification algorithms. The 
ENIGMA consortium has developed and documented criteria for the 5-tier classification of BRCA1/2 
genetic variants based on qualitative and quantitative information (http://www.enigmaconsortium.org/). 
According to these rules, and consistent with those proposed by InSiGHT for Mismatch Repair gene 
variants (1), BRCA1/2 variants considered extremely likely to alter splicing based on position (typically 
IVS±1 or IVS±2) were initially all considered Class-4 (likely pathogenic) if untested for splicing 
alterations. However, the findings presented in this study have been pivotal to support amendment to 
these classification criteria, specifying need for particular caution in interpreting variants in instances 
where 9,10 (or other known naturally occurring in-frame alternative splicing events) might rescue gene 
functionality (see Supplemental Table 3). Hence, we also recommend caution in interpreting coding 
sequence variants that lead to premature termination codons in BRCA1 exons 9 and 10. This conservative 
stance is consistent with recent American College of Medical Genetics (ACMG) guidelines (16), which 
recommend considering the presence of alternative gene transcripts, understanding which are biologically 
relevant, and in which tissues the products are expressed. Thus, caution should be exercised when 
interpreting the impact of truncating variants confined to only a subset of transcripts, given the presence 
of other protein isoforms.  
 
Of note, our results have additional implications unrelated to alternative splicing. More precisely, our 
study suggests that BRCA1 tumor suppressor activity tolerates a substantial reduction in expression level 
in vivo.  Indeed, results shown in Figure 4 indicate that a BRCA1 allele producing as much as ≈70-80% of 
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transcript encoding tumor suppressor deficient protein (as measured in blood-related samples) may not 
necessarily confer high-risk of developing cancer. This observation supports the conservative viewpoint 
of the ENIGMA consortium that, in the absence of other information, a variant can be considered 
pathogenic due to an effect on mRNA integrity if it only produces transcripts carrying a premature stop 
codon or an in-frame deletion disrupting known functional domain(s), as determined by semi-quantitative 
or quantitative methods.  
 
In brief, there are several broad messages arising from the present study. Our results confirm that mRNA 
and genetic studies are warranted to inform the clinical significance of sequence alterations at the highly 
conserved intronic dinucleotides of splice donor and acceptor sites, and highlight the need to consider 
both variant haplotype and alternative splicing events in the design and interpretation of assays assessing 
the functional consequences of variants of uncertain clinical significance. We have also shown that 
comprehensive understanding of alternative splicing, paired with clinical genetic studies, is critical to 
understand the clinical consequences of complex splicing profiles observed for certain spliceogenic 
variants. Lastly, we provide a baseline hypothesis for future investigation and interpretation of other 
likely spliceogenic BRCA1/2 variants, a hypothesis that has implications for informing standards for 
generic variant classification guidelines. 
 
Materials and Methods 
1. Genotyping and Sample Sets 
We undertook screening of BRCA1 c.594-2A>C by direct genotyping, as part of the iCOGS experiment 
detailed elsewhere (17, 18). This study included genotype and pathology results from breast cancer cases 
and controls participating in the Breast Cancer Association Consortium (BCAC; 
http://apps.ccge.medschl.cam.ac.uk/consortia/bcac//), and from carriers of BRCA1 assumed pathogenic 
19 
 
variants participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA; 
http://apps.ccge.medschl.cam.ac.uk/consortia/cimba//). In addition, via the Evidence-based Network for 
Investigating Germline Mutant Alleles (ENIGMA, http://enigmaconsortium.org/, (19)), we identified 
probands recruited through familial cancer clinics who were found to be positive for BRCA1 c.594-2A>C 
via clinical genetic testing. All study participants were enrolled into national or regional studies under 
ethically-approved protocols. 
Information was recorded for all variant carriers regarding cancer status, age at diagnosis/interview, 
breast tumor pathology (grade, and Estrogen Receptor (ER), Progesterone Receptor (PR), and Herceptin-
2 (HER2) status), and also pedigree and segregation information where available. For carriers identified 
though CIMBA and ENIGMA, the genotype for exonic variant c.641A>G (p.Asp214Gly) was sought 
from the original clinical testing report.  
The BCAC dataset included 53,354 breast cancer cases and 49,720 controls and documented age at 
diagnosis/interview from 45 studies, detailed in (17).  The denominator reduced to 24,605 cases and 
25,836 controls when including only invasive breast cancer cases and controls from the 11 studies with at 
least one observation (Supplementary Table 1). These 11 studies included only individuals of European 
ancestry, and four (MCBS, MBCCSG, KARBAC, OFBCR) had undergone testing for germline BRCA1/2 
pathogenic variants (4% - 100% of samples, depending on the BCAC study), including two of four 
studies which sampled cases on the basis of reported family history or presence of bilateral disease.  
The CIMBA dataset included 11,105 female BRCA1 pathogenic variant carriers aged ≥ 18 y from 46 
studies in CIMBA recruited through cancer genetics clinics. There were 4,845 females without report of 
cancer, 4,713 breast cancer cases, 933 ovarian cancer cases, and 614 individuals reporting both breast and 
ovarian cancer. 
By contact with submitters and examination of clinical information, it was established that 11 of the 15 
CIMBA probands overlapped with individuals included in the ENIGMA dataset, and one of proband was 
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also a participant in BCAC site (Supplementary Table 2). Only non-overlapping data was included in 
multifactorial likelihood analysis.  
 
2. Statistical methods: 
We evaluated the effect of the BRCA1 c.594-2A>C variant on breast cancer risk in BCAC, using logistic 
regression models with adjustment for censoring age and population structure, based on six principal 
components which defined any residual population sub-structure. Censoring age was defined as age at 
breast cancer diagnosis, or age at last interview/follow-up. Only case-control studies in which the variant 
was observed at least once were included in the analysis.  
In order to place case-control data into the same likelihood ratio (LR) framework as the other lines of 
evidence used for multifactorial likelihood analysis (20, 21), we compared the likelihood of the 
distribution of BRCA1 c.594-2A>C variant carriers among cases and controls under the hypothesis that 
the variant has the same age specific relative risks as the “average” pathogenic BRCA1 mutation 
compared to that under the hypothesis that it is not associated with any increased breast cancer risk. 
Specifically, we used the age at diagnosis of cases and age at interview for controls together with the 
relative risks of breast cancer estimated from case series unselected for family history (6) to calculate the 
probability that each individual carrying  BRCA1 c.594-2A>C in the sample is a BRCA1 pathogenic 
variant carrier given their affected status and age. Under the hypothesis that BRCA1 c.594-2A>C is a 
benign variant and does not confer increased breast cancer risk, we calculated the probability of the 
distribution of cases and controls among BRCA1 c.594-2A>C carriers as a simple binomial probability 
with p=proportion of cases in the sample. These two likelihoods were then compared to derive the 
appropriate LR.  
Bayes scores for segregation were derived as described previously (22), and pathology LRs were applied 
as indicated in Spurdle et al (23).  The segregation scores, pathology LRs and case-control LRs are 
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mutually independent and were combined to derive a combined odds for causality as described previously 
(20). 
We used the program Phase 2.0 (24) to estimate the most likely haplotypes of the BCAC cases and 
controls based on 29 variants in the region within and surrounding the BRCA1 locus, in order to examine 
if all c.594-2A>C variant carriers were observed on the same haplotypic background. Variants used for 
phasing were those submitted by ENIGMA for inclusion on the iCOGS chip design, the most common of 
which were rs8176258, rs1799967, rs1799950, rs4986852, and rs1799966. 
 
3. mRNA Analysis methods:  
3.1. Nomenclature. We use as reference sequences to describe BRCA1 genetic variants the GenBank 
reference sequences U14680.1 (cDNA) and NC_000017.11 (genomic). When referring to BRCA1 exons, 
we use exon numbering according to U14680.1. To characterize the BRCA1 alternative splicing landscape 
in c.[594-2A>C; 641A>G] carriers (sometimes referred throughout the text as variant allele carriers), we 
performed different RNA splicing analyses at the immediate vicinity of BRCA1 exon 10 (defined as the 
gene region spanning exons 8 to 11). Since our methodology do not allow analysis of complete transcripts 
(from 5’-end to poly(A) tail), we refer throughout the text to alternative splicing event containing 
transcripts, or alternative splicing events, rather than to alternative splicing transcripts or RNA isoforms 
(7) . For the very same reason, full-length (FL) refers throughout the text to BRCA1 exons 9- and 10-
containing transcripts (transcripts containing the exons9/10 junction defined in the GenBank reference 
sequenceU14680.1), and not necessarily to the complete 5711nt mRNA described in U14680.1. We have 
designated alternative splicing events by combining U14680.1 exon numbering with the following 
symbols:  (exon skipping), ▼ (intron retention), p (proximal, or 5'), and q (distal, or 3'). 3.2 RNA 
analysis of human samples. Up to seven contributing laboratories (sites 1 to 7) performed RNA splicing 
analyses with various methodologies, including fluorescent RT-PCR followed by capillary 
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electrophoresis, real-time quantitative PCR (qPCR), digital PCR (dPCR), Sanger sequencing, and 
RNAseq (see Supplemental Methods for further details). Experiments were performed in RNAs extracted 
from lymphoblastoid cell lines (LCLs), short-term (3-6 days) cultured Leukocytes (LEU), or fresh 
peripheral blood. RNAs were derived from 8 individual c.[594-2A>C; 641A>G] carriers (hereafter 
referred as Carriers 1 to 8) identified in four unrelated families from Australia (Carrier 1, LCL), Germany 
(Carrier 2, LCL), The Netherlands (Carriers 3 to 7, LEUs), and France (Carrier 8, peripheral blood), and 
healthy controls. We conducted several experiments designed to characterize the BRCA1 alternative 
splicing landscape observed in variant carriers. We used as quantitative description the splicing fraction 
(SF), defined here as the contribution of individual alternative splicing events to the overall BRCA1 
expression level (expressed as a percentage). As proxies for overall expression level, we used the Σ of all 
peak areas detected (capillary electrophoresis), or the signal obtained with a TaqMan assay recognizing 
the BRCA1 exons 23-24 junction (dPCR). The latter was selected since both BRCA1 exons 23 and 24 are 
likely constitutive exons (7). Note that SF is a relative measure between signals arising from the same 
locus (in this case BRCA1), so that it is neither directly related to the actual expression level on individual 
splicing events, nor with the overall expression level from that locus. It is formally possible that 
increments in the SF of one particular alternative splicing event correlate with actual reductions in the 
expression level of that splicing event. For that reason, we determine the absolute expression level of 
individual alternative splicing events by qPCR with standard curves (see supplemental methods for 
further details), and we performed relative expression analyses by dPCR, using as a reference a TaqMan 
assay recognizing the BRCA2 exons 26-27 junction. When indicated, we used as a positive control RNA 
extracted from LCLs carrying the BRCA1 variant c.591C>T [p.= (Cys197Cys)], known to increase 9SF 
and 9,10SF(14). Many experiments were performed in parallel with cultured cells treated/untreated with 
a nonsense mediated mRNA decay pathway (NMD) inhibitor, either Puromycin (Puro+/- experiments), or 
Cycloheximide (Cyclo+/- experiments). RNA from Carrier 8 was directly extracted from fresh peripheral 
blood. Biallelic expression was assessed by alternative splicing eventspecific RT-PCR followed by 
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Sanger sequencing through rs1060915 (an informative exonic SNP located at BRCA1 exon 13), using 
primers and protocols previously described (14). In addition, we searched for BRCA1 tissue specific 
alternative splicing landscape in clinically relevant samples by comparing RNAs extracted from healthy 
control fresh peripheral blood, a pool of 10 healthy breast tissues (enriched normal epithelial areas 
selected by a pathologist) adjacent to breast tumor samples, and commercial RNAs from healthy breast 
and ovarian human tissues. Experiments were performed by capillary electrophoresis of RT-PCR 
products, and by dPCR. Depending on the contributing laboratories, different RNA isolation and cDNA 
synthesis approaches were used (see Supplemental Methods for further details).     
3.3. Minigene Splicing Assays. To dissect the contribution of the individual BRCA1 variants c.594-2A>C 
and c.641A>G to the splicing alteration observed in c.[594-2A>C; 641A>G] carriers, we performed  
splicing assays with 2 different types of reported minigenes: pCAS2-BRCA1-Exon10 and pB1 (a 
minigene spanning BRCA1 exons 8 to 12). See Supplemental Methods and Figure 3 for further details.     
3.4. RNA interference experiments. To identify splicing regulatory proteins involved in BRCA1 exon 10 
splicing, we performed a series of RNA interference experiments knocking down diverse splicing 
regulatory factors (hnRNPA1, Tra2, SF2/ASF, and SC35). Experiments were performed in the breast 
cancer cell line MDAMD231 (see Supplemental Methods for further details).  
24 
 
Acknowledgements 
Funding 
The research described was supported by Spanish Instituto de Salud Carlos III funding, an initiative of 
the Spanish Ministry of Economy and Innovation partially supported by European Regional 
Development FEDER Funds [PI12/00539 and  PI15/00059 to MdH, PI13/02030 to AV]; the French 
Ministry of Higher Education and Research [to OS]; the University of Otago, Mackenzie Charitable 
Foundation, Maria Lupton, and .Health Research Council of New Zealand [to LW]; UK Higher 
Education Funding Council Senior Fellowship Scheme, the University of Southampton [to DB]; Cancer 
research UK [to DB, MR]; FamilienHede Nielsen Foundation fund [to TvOH]; Cancer Research-UK 
Senior Cancer Research Fellowship [to ACA]; National Institute of Health [CA128978 and CA11616 to 
FJC]; an NIH specialized program of research excellence in breast cancer to the Mayo Clinic [P50 
CA116201 to FJC]; and the US Breast Cancer Research Foundation [to FJC];  translational grant from 
the French National Cancer Institute and Direction Générale de l'Offre des Soins (INCa-DGOS 
AAP/CFB/CI) and a grant from the French North-West Canceropole (CNO) [to AM]; The Cancer 
Council Queensland [APP1086286 to ABS]; the NHMRC Senior Research Fellowship Scheme [ID 
1061779 to ABS]; NHMRC Project grant scheme [ID #1010719 to ABS]. 
 
Additional infrastructure support to consortium members is as follows: 
kConFab infrastructure has been supported by funding from the National Breast Cancer Foundation, 
National Health and Medical Research Council, the Queensland Cancer Fund, the Cancer Councils of 
New South Wales, Victoria, Tasmania and South Australia, and the Cancer Foundation of Western 
Australia [to kConFab, and the kConFab Clinical Follow-up study]. 
The German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) is supported by the 
German Cancer Aid (grant no 109076, Rita K. Schmutzler) and by the  Center for Molecular Medicine 
25 
 
Cologne (CMMC) 
The French consortium is supported by the French National Cancer Institute. 
EMBRACE is supported by Cancer Research UK Grants C1287/A10118 and C1287/A11990.  
BCFR was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this 
manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of 
the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade 
names, commercial products, or organizations imply endorsement by the US Government or the BCFR. 
The BBCS is funded by Cancer Research UK and Breakthrough Breast Cancer (recently merged with 
Breast Cancer Campaign forming Breast Cancer Now) and acknowledges NHS funding to the NIHR 
Biomedical Research Centre, and the National Cancer Research Network (NCRN). 
The BSUCH study was supported by the Dietmar-Hopp Foundation, the Helmholtz Society and the 
German Cancer Research Center (DKFZ). 
The CGPS was supported by the Chief Physician Johan Boserup and LiseBoserup Fund, the Danish 
Medical Research Council and Herlev Hospital 
KARBAC was supported financially through the regional agreement on medical training and clinical 
research (ALF) between Stockholm City Council and KarolinskaInstitutet, and from the Stockholm 
Cancer Foundation and the Swedish Cancer Society. 
KARBAC was supported financially through the regional agreement on medical training and clinical 
research (ALF) between Stockholm City Council and KarolinskaInstitutet, and from the Stockholm 
Cancer Foundation and the Swedish Cancer Society. 
The MARIE study was supported by the Deutsche Krebshilfee.V. [70-2892-BR I], the Hamburg Cancer 
Society, the German Cancer Research Center and the Federal Ministry of Education and Research 
(BMBF) Germany [01KH0402].   
The MARIE study was supported by the Deutsche Krebshilfee.V. [70-2892-BR I], the Hamburg Cancer 
Society, the German Cancer Research Center and the Federal Ministry of Education and Research 
26 
 
(BMBF) Germany [01KH0402].   
MBCSG is supported by grants from the Italian Association for Cancer Research (AIRC) and by funds 
from the Italian citizens who allocated the 5/1000 share of their tax payment according to Italian laws in 
support of the Fondazione IRCCS IstitutoNazionaleTumori.  
The MCBCS was supported by the NIH grant CA128978 and a Specialized Program of Research 
Excellence (SPORE) in Breast Cancer [CA116201],  the Breast Cancer Research Foundation and a 
generous gift from the David F. and Margaret T. Grohne Family Foundation and the  Ting Tsung and 
Wei Fong Chao Foundation.  
MCCS cohort recruitment was funded by VicHealth and Cancer Council Victoria. The MCCS was 
further supported by Australian NHMRC grants 209057, 251553 and 504711 and by infrastructure 
provided by Cancer Council Victoria. 
OFBCR was supported by grant UM1 CA164920 from the National Cancer Institute. The content of this 
manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of 
the collaborating centers in the Breast Cancer Family Registry (BCFR), nor does mention of trade 
names, commercial products, or organizations imply endorsement by the US Government or the BCFR. 
The pKARMA study was supported by Märit and Hans Rausings Initiative Against Breast Cancer, and 
the Swedish Medical Research Counsel. 
SEARCH was supported by grants CRUK A490/A11021, C490/A16561.   
Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework 
Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research 
UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, 
C5047/A10692), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 
CA148537, 1U19 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of 
Defence (W81XWH-10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team 
in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research 
27 
 
Foundation, and the Ovarian Cancer Research Fund.  
CIMBA data management was supported by Cancer Research-UK grant C12292/A11174 and 
C1287/A10118. 
BCAC is funded by Cancer Research UK [C1287/A10118, C1287/A12014] and by the European 
Community´s Seventh Framework Programme under grant agreement number 223175 (grant number 
HEALTH-F2-2009-223175) (COGS). 
 
We thank all the families and individuals that participated in this research. We thank Paul Pharoah and 
the Ovarian Cancer Association Consortium for providing summary information on the frequency of 
the BRCA1 c.594-2A>C variant in ovarian cancer cases and controls. 
We acknowledge the contributions of Georgia Chenevix-Trench to CIMBA and the kConFaB resource, 
and additional study-specific acknowledgements as noted below.  
NZBCS: Anne Smith, Bridget Robinson, Caroline Lintott, John Pearson, Yen Phung George Wiggins 
and the family members for their valuable contributions. 
The Netherlands Consortium:FransHogervorst for assistance in data collation, Dr. M. Olderode-
Berends from the University Medical Centre Groningen and Dr. E. van Riel from University Medical 
Centre Utrecht for providing blood samples for RNA studies, and Elsa Bik from the Leiden University 
Medical Centre, The Netherlands for excellent technical assistance. 
kConFab: Heather Thorne, Eveline Niedermayr, all the kConFab research nurses and staff, the heads 
and staff of the Family Cancer Clinics, and the Clinical Follow Up Study for their contributions to this 
resource. 
GC-HBOC: Dieter Schäfer, Center Frankfurt, for providing DNA samples and JulianeKöhler for 
excellent technical assistance.   
Northshore: Tina Selkirk for assistance in data collation. 
French Consortium: the French oncogeneticists, and the UNICANCER Genetic Group (UGG) lead by 
28 
 
Dr Catherine Noguès. 
BCFR-AU: Maggie Angelakos, Judi Maskiell, Gillian Dite, Helen Tsimiklis. 
MUV: Daniela Muhr for assistance in data collation. 
BBCS: Eileen Williams, Elaine Ryder-Mills, Kara Sargus 
BSUCH: Peter Bugert, Medical Faculty Mannheim  
CGPS: Staff and participants of the Copenhagen General Population Study. For the excellent technical 
assistance: DortheUldall Andersen, Maria BirnaArnadottir, Anne Bank, DortheKjeldgård Hansen. The 
Danish Breast Cancer Group (DBCG) is acknowledged for the tumor information. The Danish Cancer 
Biobank is acknowledged for providing infrastructure for the collection of blood samples for the cases. 
MARIE: Alina Vrieling, Katharina Buck, MuhabbetCelik, Ursula Eilber and Sabine Behrens.  
MBCSG: SiranoushManoukian, Bernard Peissel, Jacopo Azzollini and Fernando Ravagnani of the 
Fondazione IRCCS IstitutoNazionaleTumori (INT), Milan, Italy; BernandoBonanni, Monica Barile and 
Irene Feroce of the IstitutoEuropeo di Oncologia (IEO), Milan, Italy; and the personnel of the 
Cogentech Cancer Genetic Test Laboratory, Milan, Italy. 
OFBCR: Teresa Selander, NayanaWeerasooriya 
SEARCH:  Marie Mack 
COGS: Paul Pharoah,  Andrew Berchuck (OCAC), Georgia Chenevix-Trench,  Ken Offit (CIMBA), 
Alison M. Dunning, Andrew Lee,Ed Dicks, Craig Luccarini, the staff of the Centre for Genetic 
Epidemiology Laboratory, Javier Benitez, Anna Gonzalez-Neira, the staff of the CNIO genotyping 
unit, Jacques Simard, Daniel C. Tessier, Francois Bacot, Daniel Vincent, Sylvie LaBoissière, Frederic 
Robidoux, the staff of the McGill University and Génome Québec Innovation Centre, Sune F. Nielsen, 
Borge G. Nordestgaard, the staff of the Copenhagen DNA laboratory, Julie M. Cunningham, Sharon A. 
Windebank, Christopher A. Hilker, Jeffrey Meyer, the staff of Mayo Clinic Genotyping Core Facility.  
AM and INSERM: Dr Sophie Krieger for contributing with DNA samples, Prof Thierry Frébourg for 
providing patient’s samples for RNA analysis, and AurélieDrouet and Gaia Castelain for technical 
29 
 
assistance. 
 
Conflicts of Interest 
Tina Pesaran and Elizabeth Chao are paid employees of Ambry Genetics.  
30 
 
References 
1 Thompson, B.A., Spurdle, A.B., Plazzer, J.P., Greenblatt, M.S., Akagi, K., Al-Mulla, F., Bapat, B., 
Bernstein, I., Capella, G., den Dunnen, J.T. et al. (2014) Application of a 5-tiered scheme for standardized 
classification of 2,360 unique mismatch repair gene variants in the InSiGHT locus-specific database. Nat. 
Genet., 46, 107-115. 
2 Rosenthal, E.T., Bowles, K.R., Pruss, D., van Kan, A., Vail, P.J., McElroy, H. and Wenstrup, R.J. 
(2015) Exceptions to the rule: Case studies in the prediction of pathogenicity for genetic variants in 
hereditary cancer genes. Clin. Genet., 88, 533-541. 
3 Tesoriero, A.A., Wong, E.M., Jenkins, M.A., Hopper, J.L., Brown, M.A., Chenevix-Trench, G., 
Spurdle, A.B., Southey, M.C. and kConFab. (2005) Molecular characterization and cancer risk associated 
with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer families. Hum. 
Mutat., 26, 495. 
4 Whiley, P.J., de la Hoya, M., Thomassen, M., Becker, A., Brandao, R., Pedersen, I.S., Montagna, 
M., Menendez, M., Quiles, F., Gutierrez-Enriquez, S. et al. (2014) Comparison of mRNA splicing assay 
protocols across multiple laboratories: recommendations for best practice in standardized clinical 
testing. Clin. Chem., 60, 341-352. 
5 Walker, L.C., Whiley, P.J., Houdayer, C., Hansen, T.V., Vega, A., Santamarina, M., Blanco, A., 
Fachal, L., Southey, M.C., Lafferty, A. et al. (2013) Evaluation of a 5-tier scheme proposed for 
classification of sequence variants using bioinformatic and splicing assay data: inter-reviewer variability 
and promotion of minimum reporting guidelines. Hum. Mutat., 34, 1424-1431. 
6 Antoniou, A., Pharoah, P.D., Narod, S., Risch, H.A., Eyfjord, J.E., Hopper, J.L., Loman, N., Olsson, 
H., Johannsson, O., Borg, A. et al. (2003) Average risks of breast and ovarian cancer associated with 
BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 
22 studies. Am. J. Hum. Genet., 72, 1117-1130. 
7 Colombo, M., Blok, M.J., Whiley, P., Santamarina, M., Gutierrez-Enriquez, S., Romero, A., Garre, 
P., Becker, A., Smith, L.D., De Vecchi, G. et al. (2014) Comprehensive annotation of splice junctions 
supports pervasive alternative splicing at the BRCA1 locus: a report from the ENIGMA consortium. Hum. 
Mol. Genet., 23, 3666-3680. 
8 Steffensen, A.Y., Dandanell, M., Jonson, L., Ejlertsen, B., Gerdes, A.M., Nielsen, F.C. and Hansen, 
T. (2014) Functional characterization of BRCA1 gene variants by mini-gene splicing assay. Eur. J. Hum. 
Genet., 22, 1362-1368. 
9 Mark, W.Y., Liao, J.C., Lu, Y., Ayed, A., Laister, R., Szymczyna, B., Chakrabartty, A. and 
Arrowsmith, C.H. (2005) Characterization of segments from the central region of BRCA1: an intrinsically 
disordered scaffold for multiple protein-protein and protein-DNA interactions? J. Mol. Biol., 345, 275-
287. 
10 Clark, S.L., Rodriguez, A.M., Snyder, R.R., Hankins, G.D. and Boehning, D. (2012) Structure-
Function Of The Tumor Suppressor BRCA1. Comput. Struct. Biotechnol. J., 1, pii: e201204005. 
11 Starita, L.M., Young, D.L., Islam, M., Kitzman, J.O., Gullingsrud, J., Hause, R.J., Fowler, D.M., 
Parvin, J.D., Shendure, J. and Fields, S. (2015) Massively Parallel Functional Analysis of BRCA1 RING 
Domain Variants. Genetics, 200, 413-422. 
12 Shakya, R., Reid, L.J., Reczek, C.R., Cole, F., Egli, D., Lin, C.S., deRooij, D.G., Hirsch, S., Ravi, K., 
Hicks, J.B. et al. (2011) BRCA1 tumor suppression depends on BRCT phosphoprotein binding, but not its 
E3 ligase activity. Science, 334, 525-528. 
13 Savage, K.I. and Harkin, D.P. (2015) BRCA1, a 'complex' protein involved in the maintenance of 
genomic stability. FEBS J., 282, 630-646. 
31 
 
14 Dosil, V., Tosar, A., Canadas, C., Perez-Segura, P., Diaz-Rubio, E., Caldes, T. and de la Hoya, M. 
(2010) Alternative splicing and molecular characterization of splice site variants: BRCA1 c.591C>T as a 
case study. Clin. Chem., 56, 53-61. 
15 Nieuwenhuis, M.H. and Vasen, H.F. (2007) Correlations between mutation site in APC and 
phenotype of familial adenomatous polyposis (FAP): a review of the literature. Critical reviews in 
oncology/hematology, 61, 153-161. 
16 Richards, S., Aziz, N., Bale, S., Bick, D., Das, S., Gastier-Foster, J., Grody, W.W., Hegde, M., Lyon, 
E., Spector, E. et al. (2015) Standards and guidelines for the interpretation of sequence variants: a joint 
consensus recommendation of the American College of Medical Genetics and Genomics and the 
Association for Molecular Pathology. Genet. Med., 17, 405-424. 
17 Michailidou, K., Hall, P., Gonzalez-Neira, A., Ghoussaini, M., Dennis, J., Milne, R.L., Schmidt, M.K., 
Chang-Claude, J., Bojesen, S.E., Bolla, M.K. et al. (2013) Large-scale genotyping identifies 41 new loci 
associated with breast cancer risk. Nat. Genet., 45, 353-361, 361e351-352. 
18 Couch, F.J., Wang, X., McGuffog, L., Lee, A., Olswold, C., Kuchenbaecker, K.B., Soucy, P., 
Fredericksen, Z., Barrowdale, D., Dennis, J. et al. (2013) Genome-wide association study in BRCA1 
mutation carriers identifies novel loci associated with breast and ovarian cancer risk. PLoS Genet., 9, 
e1003212. 
19 Spurdle, A.B., Healey, S., Devereau, A., Hogervorst, F.B., Monteiro, A.N., Nathanson, K.L., Radice, 
P., Stoppa-Lyonnet, D., Tavtigian, S., Wappenschmidt, B. et al. (2012) ENIGMA--evidence-based network 
for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical 
significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum. Mutat., 33, 2-7. 
20 Goldgar, D.E., Easton, D.F., Deffenbaugh, A.M., Monteiro, A.N., Tavtigian, S.V., Couch, F.J. and 
Breast Cancer Information Core Steering, C. (2004) Integrated evaluation of DNA sequence variants of 
unknown clinical significance: application to BRCA1 and BRCA2. Am. J. Hum. Genet., 75, 535-544. 
21 Goldgar, D.E., Easton, D.F., Byrnes, G.B., Spurdle, A.B., Iversen, E.S., Greenblatt, M.S. and Group, 
I.U.G.V.W. (2008) Genetic evidence and integration of various data sources for classifying uncertain 
variants into a single model. Hum. Mutat., 29, 1265-1272. 
22 Thompson, D., Easton, D.F. and Goldgar, D.E. (2003) A full-likelihood method for the evaluation 
of causality of sequence variants from family data. Am. J. Hum. Genet., 73, 652-655. 
23 Spurdle, A.B., Couch, F.J., Parsons, M.T., McGuffog, L., Barrowdale, D., Bolla, M.K., Wang, Q., 
Healey, S., Schmutzler, R., Wappenschmidt, B. et al. (2014) Refined histopathological predictors of 
BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, 
CIMBA, and ENIGMA consortia. Breast Cancer Res., 16, 3419. 
24 Delaneau, O., Marchini, J. and Zagury, J.F. (2012) A linear complexity phasing method for 
thousands of genomes. Nat. Methods, 9, 179-181. 
 
32 
 
Legends to Figures  
Figure 1. Capillary Electrophoresis analyses of BRCA1alternative splicing landscape  in LCLs from 
one BRCA1c.[594-2A>C; 641A>G] carrier (Carrier 1) and 10 Controls. Panel A shows representative 
examples of capillary electrophoresis analysis of RT-PCR products generated with the E8.1-E11p assay in 
LCLs treated (Puro+) or untreated (Puro-) with the nonsense mediated decay inhibitor puromycin. The 
fluorescence intensity of each peak (Y-axis) is expressed in arbritary units (AU). The analyses detected 
the full-length transcript (FL), and up to four alternative splicing events, two in-frame (9,10 and ▼10p) 
and two out-of-frame (9, and 10). In these particular examples, ▼10p transcripts are detected only in 
Carrier 1, but we have detected ▼10p transcripts in Controls, as summarized in panel B. The presence of 
▼10p in Controls has been further confirmedby RNAseq (see Supp. Figure 3).The boxplots in Panel B 
(displaying low, Q1, median, Q3, and high values)  show the splicing fraction (SF) of in-frame transcripts 
(9,10,  FL and ▼10p) observed in Carrier 1 (3 technical replicas) and 10 Controls. SF expressed as the 
% of the corresponding peak area to the Σ of all five peak areas detected by capillary electrophoresis. This 
particular experiment was performed with the E8.2-E11q.2 assay. Note that the ▼10pSF  is rather minor 
(<1%) regardless of the LCL tested. The FL
SF
 was much lower in Carrier 1 than in Control samples. The 
boxplots in Panel C (displaying low, Q1, median, Q3, and high values) show the SF of out-of-frame 
transcripts (9 and 10) observed in Carrier 1 (3 technical replicates) and 10 Controls. The relative 
contribution of 10 to the overall signal was much higher in Carrier 1 than in Control samples. Normal 
outliers (>1.5 interquartile range, IQR) display small circles. (** represents P≤0.01) (*** represents 
P≤0.001) (ns=non-significant).  
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Figure 2.  Quantification of major in-frame transcripts 9,10 and full-length (FL) in LCLs from 
one BRCA1c.[594-2A>C; 641A>G] carrier (Carrier 1) and Controls. Experiments were performed in 
LCLs treated with Puromycin (Puro+). Panel A displays 9,10SF and FLSF, estimated as the ratio between 
the GADPH normalized absolute numbers of 9,10 (or FL) molecules and absolute number of all BRCA1 
transcripts, as determined by qPCR analysis performed with standard curves (see Supplemental Methods 
and Supplemental Figure 4). Standard deviation of 3 independent measures is shown. Panel B displays 
dPCR data measuring 9,10SF and FL (inclusion of exons 9 and 10)SF, using exon23-24 junction as a 
proxy for overall BRCA1 expression level. The precision of each measure (as determined by the 
QuantStudio 3D Analysis Cloud Software) is indicated. Two technical replicates of Carrier 1 are shown.  
We included as positive control a LCL carrying the BRCA1 c.591C>T variant, known to increase 9,10SF. 
The 9,10SF in Carrier 1 was higher than in Controls (24% in two technical replicates of Carrier 1 vs. an 
average of 17% in 7 control samples, Mann-Whitney U test; p=0.028 for difference between groups), but 
a 50% reduction of FL
SF 
(50% in two technical replicas of Carrier 1 vs. an average of 94% in 6 control 
samples, Mann-Whitney U test; p=0.036 for difference between groups). 
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Figure 3.  Analysis of BRCA1 c.594-2A>C and c.641A>G variants with splicing reporter minigene 
assays. The figure shows schematic non-scale representations of the splicing reporter minigenes pCAS2-
BRCA1-exon10 (panel A) and pB1 (panel B) used for splicing assays. Minigenes were constructed as 
described under Supplemental Methods. PCMV indicates the cytomegalovirus promoter, boxes represent 
exons and lines in between indicate introns. BRCA1 sequences are highlighted in black. Arrows represent 
primers used in RT-PCR reactions. With the exception of pB1 BRCA1 intron 11 (402 nt-long full-length 
IVS11), minigenes harbor partial segments of BRCA1 introns. For comparative purposes, the size in 
nucleotides of each segment is shown together with the size corresponding to the endogenous full-length 
BRCA1 introns shown in brackets. As indicated, pB1 carries an additional cytosine (+3insC) in exon 8 to 
keep the ORF with -globin exon 1 (Raponi et al., 2012).  Splicing assays were performed by analyzing 
the splicing pattern of WT and mutant minigenes (c.594-2A>C, c.641A>G, and c.[594-2A>C; 641A>G]) 
transiently expressed in human cells (HeLa, COS-7, MCF7, HBL100 or IGROV-1) as described under 
Supplemental Methods. The images show RT-PCR products separated in ethidium bromide-stained 
agarose gels. FL, full-length; 9, exon 9 skipping; 10, exon 10 skipping; 9,10, skipping of both exons 
9 and 10;  *, retention of 21 intronic nucleotides immediately upstream exon 10 (▼10p). One can note 
that: (i) the relative level of alternatively spliced pB1(WT) transcripts is higher in IGROV-1 than in 
HeLa, MCF-7, or HBL100 cells, and (ii) the predominant alternative splicing event of pB1(WT) in these 
cell lines is 10, whereas that of endogenous wild-type BRCA1 in blood related samples is  9,10 (Figure 
4 and Supplemental Figures 1 and 2).   
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Figure 4. Combined genetic and splicing analyses of BRCA1 c.[594-2A>C; 641A>G] and BRCA1 
c.591C>T supports a BRCA19,10 rescue model with far-reaching clinical implications. Panel A 
(top) shows the splicing fraction (SF) of five alternative splicing events detected by capillary 
electrophoresis analysis of RT-PCR products generated with the E8.2-E11q.2 assay (Puro+ experiments, 
36 cycle PCRs, see Figure 1 and Supplemental Figure 1 for further details). As shown, this description of 
the BRCA1 alternative splicing landscape in the vicinity of exon 10 is different in healthy control samples, 
c.[594-2A>C; 641A>G] carriers, and c.591C>T carriers. Yet, we show in the present study that none of 
these 3 BRCA1 splicing landscapes is associated with high risk of developing BRCA1 related cancers. The 
chart displays SFs that, in carriers, represent a combined signal from the variant allele and the 
accompanying WT allele. Panel A (bottom). Deduced per allele SFs are shown. Assuming that SFs 
arising from the accompanying WT allele equal to the average SFs observed in 10 Control samples (as 
shown in the central chart bar), we deconvoluted the SFs corresponding to c.[594-2G; c.641G]  (left chart 
bar) and c.591T  (right chart bar) alleles. Panel B. The cartoon represents the relative per allele (100% 
equals to the overall expression level arising from one individual allele) and per cell (100% equals to the 
overall expression arising from a diploid genome) expression (BRCA1 exons 7 to 11) in a c.[594-2G; 
c.641G] carrier, inferred from capillary EP analyses shown in Panel A. For simplicity, only FL and 9,10 
transcripts are shown, albeit 9 and ▼10p transcripts account for ≈5% of the per cell expression. 
Truncating (out-of-frame) events are highlighted with a red cross.  The analysis suggests that expressing 
up to ≈35% of BRCA1 PTC-NMD transcripts (per diploid genome) is not associated with high-risk of 
developing cancer. The analysis suggests as well that a BRCA1 allele expressing up to ≈70% (per allele) 
BRCA1 PTC-NMD transcripts is not associated with high-risk of developing cancer (a relevant finding in 
the context of the two-hit model). Panel C. The cartoon represents the relative per allele (100% equals to 
the overall expression level arising from one individual allele) and per cell (100% equals to the overall 
expression arising from a diploid genome) expression (BRCA1 exons 7 to 11) in a c.591C>T carrier, 
inferred from capillary EP analyses shown in Panel A. For simplicity, only FL, 9,10 and 9 (variant 
allele) are shown, albeit 9 (wt allele), 10 (wt and variant allele), and ▼10p (wt and variant allele) 
transcripts account for ≈5% of the per cell expression. The data strongly suggests that BRCA19,10 
transcripts, representing up to 51% (per diploid genome) and up to 71% (per allele) of the overall BRCA1 
expression code for a BRCA1 protein with tumor suppressor activity. The model displayed in this figure 
is intended to illustrate the most relevant findings of our study. Yet, some limitations should be 
highlighted. First, the model assumes (based on 36-cycle PCR capillary EP data) that 9,10SF in Controls 
and c.[594-2A>C; 641A>G] carriers is ≈29%, while other experiments suggests that the actual value is 
probably lower in both instances (Figure 2, Supplemental Figure 2), albeit slightly increased in Carriers 
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vs. Controls. The model has been elaborated with data obtained in LCLs, not in clinically relevant tissues 
such as breast or ovarian. 
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Abbreviations 
 
Cyclo-  Cycloheximide absent 
Cyclo+ Cycoeximide present 
dPCR digital PCR 
qPCR quantitative PCR 
FL  full-length 
LCL  lymphoblastoid cell line 
LEU  leukocyte 
NMD  nonsense mediated decay  
PTC  premature termination codon 
Puro-  Puromycin absent 
Puro+  Puromycin present 
qPCR quantitative PCR 
RNAseq high-throughput RNA sequencing 
RT       reverse transcription 
SF  splicing fraction 
siRNA small interference RNA 
WT  wildtype 
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Supplemental Figure 1. BRCA1 alternative splicing landscape in LCLs from one BRCA1 c.[594-2A>C; 
641A>G] carrier (Carrier 1) and 10 Controls.  Panel A shows a schematic representation of the c.[594-
2A>C; 641A>G]  variant allele under investigation. Panel B Capillary electrophoresis analysis of RT-PCR 
products generated with the E8.2-E11q.2 assay  (36 PCR cycles) detects up to five different alternative splicing 
events both in c.[594-2A>C; 641A>G] carriers and Controls, including 3 in-frame (9,10,  Full-length (FL) and 
▼10p), and 2 out-of-frame (9 and 10) events (see Figure 1).  The charts represent the splicing fraction (SF) 
of these five splicing events (expressed as the % of the corresponding peak area to the Σ of all five peak areas) 
observed in Carrier 1 (average of 3 technical replicas) and Controls (average of 10 different samples). The 
analysis shows that increased 10SF (and corresponding decrease of FLSF) is the predominant effect observed in 
carriers. The data is compatible as well with ▼10p being up-regulated in carriers (as predicted by splicing 
reporter minigene experiments, Figure 3), but splicing fractions are too low both in Carrier 1 (0.6% in Puro+ 
and 1% in Puro- experiments) and controls (0.3% in Puro+ and 0,2% in Puro- experiments) to be reliable 
measured by capillary electrophoresis. Note that SFs observed in experiments performed with or without 
Puromycin are different, suggesting nonsense-mediate decay (NMD) of out-of-frame 9 and 10 transcripts in 
Puro- experiments. In the case of Controls, differences are subtle, since 9SF (3,4% in Puro+ and 1,2% in Puro- 
experiments) and 10SF (1,1% in Puro+ and 0,8% in Puro- experiments) are rather minor contributors to the 
overall expression level. However, differences  in Carrier 1 are significant, due to the fact that 10 is a 
predominant contributor to the overall expression level in carriers (10SF of 38% in Puro+ experiments and 16% 
in Puro- experiments). The experiments summarized in this figure, as well as most experiments reported in the 
present study, restrict the characterization of BRCA1 alternative splicing landscape to the vicinity of BRCA1 
exon 10 i.e. we have not characterized/isolated complete transcripts. For this reason, we refer throughout the 
text to alternative splicing events rather than to alternative splicing transcripts. 
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Supplemental Figure 2. 9,10 (and 9,10+11q), 10 (and 10+11q), FL and 11q SF determined by 
capillary electrophoresis in up to 8 independent c.[594-2A>C;641A>G] carriers. The boxplots in Panel A 
(displaying low, Q1, median, Q3, and high values)  summarize experiments performed by four contributing 
laboratories (sites 1 to 4) in two independent LCL carriers named Carrier 1, and Carrier 2 , one fresh blood 
sample (PAXgene system for blood sampling, no puromycin/cycloheximide treatment) named Carrier 8, and its 
corresponding control. Note the high level of 10 transcripts in Carrier 8, despite the fact that NMD is not 
inhibited by the PAXgene system (C) samples. In the case of carriers, N represents the number of technical 
replicates. Site 1 data (the same data summarized in Supplemental Figure 1) was generated with the E8.2-
E11q.2 RT-PCR assay (36 PCR cycles). Site 2 data was generated with the E8.1-E11q1 RT-PCR assay (36 PCR 
cycles). Site 3 data was generated with the E7-E11q.1 RT-PCR assay (40 PCR cycles). Finally, Site 4 data was 
generated with the E8.2-E11q.2 RT-PCR assay (30 PCR cycles).  All RT-PCR assays are described in 
Supplemental Methods Table 1. Panel B summarizes experiments performed by site 5 in five independent 
leukocytes (LEU) carriers (Carriers 3 to 7) and seven controls. Data was generated with the E8.1-E11q1 RT-
PCR assay (28 PCR cycles). Panel C summarizes experiments identical to those described in Panel B, except 
that the reverse primer mapped to exon 12 (E8.1-E12 RT-PCR assay). Note that in this case, the SF is not 
calculated relative to the “overall BRCA1 expression level”, but to the “overall BRCA1 11q expression level”. 
Since BRCA1 exon11q (3309nt) is too long to be PCR amplified with standard protocols for short amplicons, 
this primer combination allowed us to analyse alternative splicing in the subpopulation of BRCA1 transcripts 
lacking exon 11q. Standard deviations are shown. When indicated, LCLs were treated with Puromycin (Puro+), 
or Cycloheximide (Cyclo+), prior to RNA extraction. 
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Supplemental Figure 3.  RNAseq data in one BRCA1 c.[594-2A>C; 641A>G] carrier (Carrier 1) and 
Controls. Expression data were generated using the TruSeq Targeted RNA Expression platform (Illumina) 
and RNA from 11 LCLs (10 Controls and Carrier 1). Splice junction reads defining 47 different BRCA1 
alternative splicing events were identified in at least one sample of the analyzed cohort.  For simplicity, only 
BRCA1 splicing events  involving exons 7 to 12 are shown in the heatmap (Panel A).  The color key indicates 
the number of reads at exon-exon junctions defining each splicing event. Cyclo+ (T) and Cyclo – (U) 
experiments were performed. Experiments show the presence of ▼10p transcripts in Control samples, as well 
as absence of c.[594-2A>C; 641A>G] specific splice junctions, thus confirming capillary electrophoresis 
findings. Panel B shows the relative proportion of sequence reads for BRCA1 ∆10 (exons 9/11 junction) and  
exon 10 inclusion (exons 10/11 junction) relative to BRCA1 exons2/3 junction (upper chart), or BRCA2 exons 
22/23 junction (bottom chart). Mean value and standard deviation for 10 Controls is indicated in grey. Only 
Cyclo+ experiments are shown. 
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Supplemental Figure 4. qPCR analysis of BRCA1 alternative splicing landscape in LCLs from one 
BRCA1 c.[594-2A>C; 641A>G] carrier (Carrier 1) and 11 Controls.  We performed several quantitative 
real-time PCR (qPCR) experiments with standard curves to determine the GADPH normalized absolute 
number of BRCA1 FL transcripts (exon 9 and exon 10 containing transcripts), as well as BRCA1 transcripts 
containing the following alternative splicing events : 9,10, 9, 10,  9_11, 11q, 11, and 9,10+11q. 
The chart in Panel A displays the normalized absolute number of FL transcripts in Carrier 1 and 11 
Controls (standard error of 3 experiments is shown), as well as the normalized absolute number of all 
BRCA1 transcripts (see supplemental methods for further details). The data indicate that the level of exons 
9 and 10 containing transcripts drops in Carrier 1 if compared with healthy controls, but the overall BRCA1 
expression level remains roughly constant.   The Chart in Panel B shows 9_11SF, 11SF, and  
(9,10+11q)SF estimated as the ratio between the GADPH normalized absolute number of transcripts 
containing the indicated alternative splicing event, and the GADPH normalized absolute number of all 
BRCA1 transcripts shown in Panel A (standard error of 3 experiments in shown). As already observed for 
9,10SF (see Figure 2), the (9,10+11q)SF appears to be slightly increased in Carrier 1 if compared with 
healthy control samples. 
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Supplemental Figure 5. Biallelic expression analyses in LEUs from one BRCA1 c.[594-2A>C; 
641A>G] carrier (Carrier 3) and one Control.  The figure shows representative examples of RT-
PCR sequencing at the informative SNP rs1060915 (c.4308C>T, p.=), located in BRCA1 exon 13. RT-
PCR amplifications were performed with a reverse primer located in BRCA1 exon 15, and different 
forward primers (left) designed to be specific for certain alternative splicing events. Since BRCA1 
exon 11 is too long to be PCR amplified with our protocol, experiments shown in panel A are 
restricted to the subset of BRCA1 11q transcripts, as indicated (right). A forward primer located in 
exons12/13 junction (panel B) is considered a proxy for overall expression. In Carrier 3, the 
rs1060615 C allele was demonstrated to be in cis with c.[594-2A>C;641A>G] (data not shown). 
Overall, data obtained with exons8/11 junction forward primer (panel A, top) shows that in carriers, 
both alleles contribute similarly to 9,10 overall expression level. A slight imbalance in favor of the 
variant allele (c.4308C) observed in Carrier 3 is compatible with other results suggesting that levels of 
9,10 transcripts in  c.[594-2A>C; 641A>G]  carriers is in the upper limit of Control samples (Figure 
2, Supplemental Figure 6). Data obtained with exons 9/11 junction forward primer (panel A, bottom) 
shows that 10 transcripts arise mostly from the variant allele. Panel B shows similar experiments 
performed with exons 12/13 forward primers, a proxy for overall expression level. The data suggests a 
slight imbalance in favor of the WT allele (c.4308T) in Carrier 3. The data is compatible with selective 
degradation of variant-derived 10 transcripts in the absence of a NMD inhibitor (Cyclo- 
experiments). Equivalent experiments performed with Carriers 4 and 5 showed almost identical 
results, including the slight imbalance observed with forward primers located in junctions for exons 
8/11 and exons 12/13 (data not shown).  
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Supplemental Figure 6.  dPCR relative quantification of 9,10 and FL in-frame transcripts in 
LCLs from one BRCA1 c.[594-2A>C; 641A>G] carrier (Carrier 1), one c.591C>T carrier, and 7 
Controls. LCLs were treated with the NMD inhibitor Puromycin (Puro+ experiments) prior to RNA 
extraction and analysis. The boxplot in Panel A (displaying low, Q1, median, Q3, and high values) 
shows digital PCR measures of BRCA1 9,10  relative expression level (exons8/10 junction), using 
BRCA2 as a reference). The data is expressed as the fold-increase relative to the average of 7 Controls. 
BRCA1 9,10  relative expression level in Carrier 1 (2 technical replicates) is in the upper limit of 
control samples, while a >2-fold increase is observed in the c.591C>T carrier. The boxplot in Panel B 
(displaying low, Q1, median, Q3, and high values) shows digital PCR measures of BRCA1 FL relative 
expression level (exons 9/10 junction), using BRCA2 as a reference. The data is expressed as the fold-
increase relative to the average of 7 Controls. A 50% decrease of BRCA1 FL relative expression is 
observed both in Carrier 1 (2 technical replicates) and c.591C>T carrier.  
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Supplemental Figure 7. BRCA1 c.641A>G is predicted to induce exon 10 skipping by altering 
potential splicing regulatory elements. Panel A displays results from a comparative in silico analysis 
of BRCA1 WT and BRCA1 c.641A>G based on ESRseq scores, which was performed as described 
under Supplemental Methods. The bars indicate the ESRseq scores of hexamer stretches starting at the 
positions indicated in the X-axis. All hexamer sequences overlapping the c.641 position were taken 
into account.  Of note, positive ESRseq scores are indicative of potential exonic splicing enhancer 
elements (ESE) whereas negative ESRseq scores indicate potential exonic silencer elements (ESSs). 
The negative nature of the Change in Total ESRseq score produced by the variant relative to WT 
(tESRseq=-1.72) is predictive of exon 10 skipping. Panel B shows a representative example of 
knockdown experiments performed in MDA-MD231 breast cancer cells demonstrating a positive role 
of Tra2 in BRCA1 exon10 inclusion.  Panel C shows representative examples of pB1long(WT) 
splicing reporter minigene experiments performed in MCF7 breast cancer cells. The pB1long(WT) 
splicing reporter minigene is identical to pB1(WT) with the only exception that it includes the full 
intron 9 and intron 10 sequences. Even if extensive alternative splicing is observed for pB1long(WT)  in 
MCF7 cells, 10 appears to be the predominant alternative splicing event (and not 9,10, which is the 
predominant endogenous BRCA1 splicing event both in blood-related samples and in MDA-MD231 
cells). pB1long(WT) results are similar to those obtained with pB1(WT)(Figure 3B). These observations 
may reflect BRCA1 tissue-specific alternative splicing and/or a suboptimal capacity of splicing 
reporter minigenes to fully reproduce the alternative splicing pattern of the exon 8-exon 11 region.  
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Supplemental Figure 8. BRCA1 alternative splicing landscape in blood, breast, and ovary related 
samples. Panel A (left) shows representative examples of capillary electrophoresis analysis o RT-PCR 
products generated with the E8.1-E11q.1 assay (33 cycle PCRCs) performed in fresh peripheral blood 
from healthy controls, non-malignant breast related samples, and non-malignant ovary related samples. 
The analyses detected full-length (FL), and up to four alternative splicing events, including two in-frame 
(9,10 and ▼10p), and two out-of-frame (9, and 10). ▼10p transcripts are not detected in the 
individual examples shown in panel A, but have been occasionally detected in blood and non-malignant 
breast samples (data not shown).  The boxplots in Panel A (displaying low, Q1, median, Q3, and high 
values) represent 9,10SF and FLSF as determined with the E8-E11p capillary electrophoresis assay 
(expressed as the % of the corresponding peak area to the Σ of all peak areas). The chart displays the SF 
observed in 23 blood samples (fresh peripheral blood from healthy controls), non-malignant breast-related 
samples 
¥
(N=2 stands for a pool of 10 non-malignant breast tissues measured in duplicate, plus one 
commercial source of non-malignant breast tissue measured in triplicate), and non-malignant ovary-
related samples 
¥
(N=1 stands for one commercial pool of 3 non-malignant ovary tissues measured in 
duplicate). Normal outliers (>1.5 inter quartile range, IQR) display a small circle. Extreme outliers (>3 
IQR) display an asterisk. Note that two c.591C>T carriers, positive controls known to increment 9,10SF, 
are correctly detected as extreme outliers in this assay. Panel B displays 9,10SF as determined by digital 
PCR (using exon23-24 junction as a proxy for overall expression, see methods for further details). The 
precision of each measure (as determined by the QuantStudio 3D Analysis Cloud Software) is indicated. 
We included in the analysis fresh blood from 18 unrelated healthy controls, fresh blood from 5 positive 
controls (5 unrelated carriers of the BRCA1 c.591C>T variant), one commercial source of non-malignant 
breast tissue, and one commercial pool of 3 non-malignant ovary tissues. For breast and ovarian samples, 
two technical replicas are shown. 
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 Supplementary Table 1:  Characteristics of Carriers of BRCA1 c.594-2A>C identified in BCAC 
 
   Description of Studies with carriers identified Characteristics of carriers identified
Study 
Acronym 
Study Design 
Country 
of Origin 
BRCA1/2 
Sequencing of 
cases in this study 
n  
Invasive 
Cases 
n  
Controls 
Case-
Control 
Status 
Age  
Interview/ 
Onset 
Breast Tumour 
Pathology 
Tumour 
Likelihood 
Ratio 
BBCS 
Cancer registry and National Cancer 
Research network based cases (including 
bilateral cases),  population based controls 
United 
Kingdom 
none tested  1446 1397 
case 43 Grade 3, ER-pos 0,64 
control 58 control 1,00 
BSUCH 
Hospital based cases, blood donor 
controls 
Germany none tested  815 954 case 40 NA 1,00 
CGPS 
Population-based cohort, nested case-
control study 
Denmark none tested  2811 4086 
case 60 Grade 2, ER-neg 2,34 
control 28 control 1,00 
KARBAC 
Hospital-based familial and consecutive 
cases, geographically matched controls 
Sweden 100% tested** 722 662 control* 61 control 1,00 
MARIE Population-based case-control study Germany none tested  1656 1778 control 54 control 1,00 
MBCSG 
Clinic-based familial/early onset breast 
cancer cases, population-based controls 
Italy 100% tested** 189 400 control 35 control 1,00 
MCBCS Hospital-based case-control study USA 4% tested**  1546 1931 control 31 control 1,00 
MCCS Population-based prospective cohort study Australia none tested  614 511 case 76 Grade NA, ER-pos 0,37 
OFBCR 
Population-based familial case-control 
study 
Canada 68% tested** 1156 511 
case 54 Grade 2, ER-pos 0,34 
case*** 41 Grade 3, ER-neg 3,16 
pKARMA 
Population-based cases, mammography 
screen study controls 
Sweden none tested  4553 5537 control 46 control 1,00 
SEARCH Population-based case-control study 
United 
Kingdom 
none tested  9097 8069 
case 46 Grade NA, ER-pos 0,37 
control 70 control 1,00 
control 52 control 1,00 
Totals 
 
 
 
24605 25836 
    
 
 
For further details about participating BCAC studies, please see Michaelidou et al (1). 
 * Age data not available, mean diagnosis age for that study used for case-control likelihood analysis 
** BCAC studies which had undergone genetic testing for BRCA1/2 variation, and were excluded from final analyses to determine causality based on case-control presentation.  
*** Case determined to overlap with a CIMBA proband. No segregation data was available, and pathology information was included only once in multifactorial likelihood 
analysis. 
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Supplementary Table 2: Characteristic of carriers of BRCA1 c.594-2A>C identified in ENIGMA and 
CIMBA* 
 
          
Consortium Site 
Country of 
Origin 
Segregation 
Bayes Score for 
Family 
Breast Tumour 
Pathology (age onset) 
for proband; other 
carrier relatives 
Pathology 
LR 
ENIGMA Ambry Genetics USA Not informative ER-pos (<50) 0.32 
ENIGMA Ambry Genetics USA Not informative ER-neg (<50) 2.60 
ENIGMA Ambry Genetics USA Not informative ER-pos (>50) 0.37 
ENIGMA Ambry Genetics USA Not informative ER-neg (<50) 2.60 
ENIGMA Ambry Genetics USA Not informative ER-pos (>50) 0.37 
ENIGMA Ambry Genetics USA Not informative ER-pos (>50) 0.37 
ENIGMA Ambry Genetics USA Not informative ER-neg (<50) 2.60 
ENIGMA/CIMBA Embrace UK 1.64 Grade 3, ER-pos (>50)  0.90 
ENIGMA/CIMBA Embrace UK Not informative Grade 1, ER NA (<50) 0.13 
ENIGMA French Consortium France 0.73 Grade 3, ER-pos (<50)  0.64 
ENIGMA French Consortium France 0.83 Grade NA, ER-neg (>50) 3.31 
ENIGMA French Consortium France 1.00 NA 1.00 
ENIGMA GC-HBOC Germany 0.42 NA 1.00 
ENIGMA GC-HBOC Germany 0.55 NA 1.00 
ENIGMA GC-HBOC Germany 2.38 
Grade 3, ER-pos (<50); 
Grade 3, ER-pos (<50) 
0.41 
ENIGMA/CIMBA GC-HBOC Germany Not informative Grade 3, ER-pos (<50) 0.64 
ENIGMA GC-HBOC Germany Not informative NA 1.00 
ENIGMA GC-HBOC Germany Not informative Grade 3, ER-pos (>50) 0.90 
ENIGMA GC-HBOC Germany Not informative Grade 3, ER-pos (>50) 0.90 
ENIGMA GC-HBOC Germany Not informative Grade 3, ER-pos (>50) 0.90 
ENIGMA GC-HBOC Germany 6.85 
Grade 3, ER-pos (<50); 
Grade 3, ER-pos (>50); 
Grade 3, ER-pos (>50); 
Grade 3, ER-pos (>50) 
0.47 
ENIGMA/CIMBA kConFab Australia 4.37 Grade 3, ER-pos (>50)  0.90 
ENIGMA/CIMBA Leiden Netherlands 0.10 NA 1.00 
ENIGMA 
New Zealand 
Familial Breast 
Cancer Study 
New 
Zealand 
0.65 NA 1.00 
ENIGMA Northshore USA 1.82 
Grade 1, ER-pos (>50); 
Grade NA, ER-pos (>50) 
0.04 
ENIGMA/CIMBA Northshore USA 0.02 NA 1.00 
ENIGMA/CIMBA Northshore USA 1.18 NA 1.00 
ENIGMA 
Adult Genetics 
Unit, South 
Australia 
Australia Not informative Grade 2, ER-pos (>50) 0.34 
CIMBA BCFR-AU Australia 1.96 NA 1.00 
CIMBA NIH USA Not informative 
NA (ovarian cancer 
patient) 
1.00 
CIMBA MUV Austria Not informative Grade 2, ER-pos (<50) 0.21 
* BRCA1 c.641 A>G (Asp214Gly) was reported to be present in all family probands.  BRCA1 c.641 A>G was also 
observed in an additional 13 carriers of BRCA1 c.594-2A>C identified by Ambry Genetics, excluded from causality 
analysis because of unavailability of relevant information.  NA=not available.  
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Supplemental Table 3: BRCA1 and BRCA2 exon boundary variants predicted/known to increase the level of naturally occurring in-frame 
RNA transcripts that may rescue gene functionality. Variants at these positions should be considered class 3 (uncertain) unless proven 
otherwise.*  
Gene 
Alternative 
Splicing Event 
Variants 
Implicated 
Rationale 
BRCA1  
 
8p 
 
c.442-1 (IVS7-1) 
c.442-2 (IVS7-2) 
Exon 8 acceptor site is an experimentally validated tandem acceptor site (NAGNAG) subject to 
alternative splicing (2). c.442-1,-2 variants are predicted to inactivate the proximal (5’), but not 
the distal (3’) splice acceptor site, thus potentially producing 8p transcripts. 
9,10 
c.548-1 (IVS8-1) 
c.548-2 (IVS8-2) 
c.593 to non-G 
c.593+1 (IVS9+1) 
c.593+2 (IVS9+2) 
c.594-1 (IVS9-1) 
c.594-2 (IVS9-2) 
c.670 to non-G 
c.670+1 (IVS10+1) 
c.670+2 (IVS10+2) 
Carriers of these variants are predicted to produce normal (or increased) levels of BRCA1 
(9,10), a major in-frame alternative splicing event (2). 
 
BRCA1 c.[594-2A>C; 641A>G] has been reported to demonstrate clinical characteristics 
inconsistent with a high risk of cancer expected for a pathogenic BRCA1 variant (3). 
13p 
 
c.4186-1 (IVS12-1) 
c.4186-2 (IVS12-2) 
Exon 13 acceptor site is an experimentally validated tandem acceptor site (NAGNAG) subject to 
alternative splicing (2). c.4186-1,-2 variants are predicted to inactivate the proximal (5’), but not 
the distal (3’) splice acceptor site, potentially producing 13p transcripts. 
14p 
 
c.4358-1 (IVS13-1) 
c.4358-2 (IVS13-2) 
Exon 14 acceptor site is an experimentally validated tandem acceptor site (NAGNAG) subject to 
alternative splicing (2). c.4358-1,-2 variants are predicted to inactivate the proximal (5´), but not 
the distal (3’) splice acceptor site, potentially producing 14p transcripts. 
BRCA2  
12 
c.6842-1 (IVS11-1) 
c.6842-2 (IVS11-2) 
c.6937 to non-G 
c.6937+1 (IVS12+1) 
c.6937+2 (IVS12+2) 
Carriers of these variants are predicted to produce exon12 skipping. BRCA2 12 is a naturally 
occurring in-frame splicing event (ENIGMA Splicing Working group, unpublished data). 
BRCA2 exon12 is functionally redundant (4). 
* Reference sequences: BRCA1 cDNA U14680.1/genomic NC_000017.11/(exon numbering according to U14680.1); BRCA2 cDNA U43746.1/genomic NC_000013/(exon numbering according to U43746).  
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Supplemental Methods 
 
Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the 
relevance of naturally occurring in-frame transcripts for developing disease gene 
variant classification algorithms. 
de la Hoya et al. 
 
Splicing Analyses  
1.1 Samples 
RNA extraction protocols from lymphoblastoid cell lines (LCLs), leukocytes (LEU) (3-6 days 
cultured), and biopsy samples were performed with standard methods that have been 
described previously (1-4). In the case of peripheral blood collected in PAXgene tubes 
(Qiagen, Hilden, Germany), RNA extraction was performed with the PAXgene Blood RNA 
kit according to the manufacturer’s instructions (Qiagen, Hilden, Germany). When indicated, 
Puromycin (Puro) or Cycloheximide (Cyclo) was added to cell cultures (end concentration of 
100µg/ml) 6-8 hours prior to cell harvest.  In addition, we used commercially available total 
RNA (guanidium thiocyanate isolation method) from Human Mammary Gland and Human 
Ovary (Clontech, Mountain View, CA). More precisely, Human Mammary Gland RNA 
(Clontech, catalog No: 636576) was obtained from a 27 year-old Caucasian female. Human 
Ovary RNA (Clontech, catalog No: 636555) was pooled from 3 Caucasian females, aged 40, 
55 and 51. In all cases, RNA samples were treated with RNase-Free DNase previous to 
Reverse Transcription (RT) reactions. For RT-PCR reactions, different contributors used 
different commercially available kits (SuperScriptII Reverse Transcriptase, Invitrogen, 
Carlsbas, CA; High Capacity RNA-to-cDNA Mater Mix, Applied Biosystems, Foster City, 
CA; Primescript RT reagent kit, Takara Biotechnology, Shiga, Japan; Transcriptor High 
Fidelity cDNA synthesis Kit, Roche Applied Science, Mannheim, Germany; One-Step RT-
PCR kit, Qiagen, Hilden, Germany) in combination with oligodT and/or random hexamers. 
Previously, we have shown that different RNA extraction/cDNA synthesis protocols are 
indistinguishable for the purpose of BRCA1 RT-PCR analyses (2).    
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1.2 Capillary Electrophoresis 
Capillary electrophoresis analysis of alternative splicing has been extensively described 
previously (2, 3). In the present study, we have analyzed the BRCA1 alternative splicing 
landscape at the vicinity of exon 10 with up to five different RT-PCR assays: E7-E11q.1, 
E8.1-E11p, E8.1-E11q.1, E8.1-E11q.2, E8.2-E11q.2, and E8.1-E12 (see Table 1 below for 
further details). To perform semi-quantitative analyses, we kept a low number of PCR cycles 
(depending on the contributing laboratory, 28, 33, or 36 cycles). While 28 or 33 cycle PCRs 
are optimal for semi-quantification, 36 cycle PCRs were needed to detect the rather minor 
alternative splicing event ▼10p. Depending on the contributing laboratory, capillary 
electrophoresis analyses were performed with 3100, 3130, 3130XL, 3500XL, or 3730XL ABI 
PRISM Genetic Analyzers (Applied Biosystems, Foster City, CA) using POP-7 filled 
capillary arrays of 36 or 50 cm. Size-calling and peak areas were analyzed with GeneMapper 
v4.0 or GenScan v3.7 software (both from Applied Biosystems, Foster City, CA), or 
GeneMarker 2.4 (Softgenetics LLC, State College, PA). As internal size-standard, we used 
LIZ-500 or LIZ-1000 (Applied Biosystems, Foster City, CA). Splicing Fraction (SF) of each 
individual alternative splicing event were measured in all cases as the ratio between the peak 
area of the individual events and the Σ of all peak areas (all transcripts) detected by the 
corresponding assay. For instance, 9,10SF is determined in a E8-E11q assay as  the ratio 
between 9,10 peak area and the Σ of 9+10+▼10p+9,10+full-length (FL) peak areas 
(depending on samples an PCR cycles, not all five peaks are necessarily observed in all 
determinations). Electropherograms with saturated peaks were not considered for SF analyses. 
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Table 1. Description of RT-PCR assays used in the present study. 
For each RT-PCR assay, we show the sequence of forward and reverse primers, mapping to the Ensembl sequence ENST00000357654 (NCBI 
NM_007294.3), and the expected size of the peaks corresponding to different BRCA1 alternative splicing events. The actual size calling may vary ±2bp with 
respect to the expected size due to factors such as local density of size-standard peaks, capillary array length, and/or Taq polymerase addition of a 3'-adenine 
overhang. 
a
 Capillary electrophoresis analysis of RT-PCR products generated with the E7-E11q.1 assay produces ±3bp doublet peaks due to alternative 
splicing at  BRCA1 exon 8 NAGNAG splicing acceptor site (3, 5). 
b
 With protocols used in the present study, the E8.1-E12 RT-PCR assay do not generate 
products spanning the long BRCA1 exon 11 (3426nt). For that reason, the expected size peaks displayed in the table correspond to BRCA1 11q transcripts 
(3, 5): 9,10+11q, 10+11q , 9+11q  and ▼10p+11q transcripts.   
RT-PCR 
assay 
Forward primer Reverse primer (FAM-labeled) Capillary Electrophoresis Analysis of RT-PCR products 
(expected peak sizes expressed in bp) 
mapping seq mapping seq 9,10 10 9 FL ▼10p 
E7-E11q.1 
c.372_c.393 
(Exon 7) 
CATCCAAAGTATGGGCTACAGA 
c.799_c.819 
(Exon 11q) 
TGGCTCCACATGCAAGTTTG 324/327a 368/371a 401/404a 445/448a 466/469a 
E8.1-E11p 
c.459_c.478 
(Exon 8) 
TGTCCAACTCTCTAACCTTG 
c.759_c.778 
(Exon 11p) 
TTTCTGGATGCCTCTCAGCT 199 243 276 320 341 
E8.1-E11q.1 
c.459_c.478 
(Exon 8) 
TGTCCAACTCTCTAACCTTG 
c.799_c.819 
(Exon 11q) 
TGGCTCCACATGCAAGTTTG 240 284 317 361 382 
E8.2-E11q.2 
c.462_c.971 
(Exon 11) 
CCAACTCTCTAACCTTGGAACTGTG 
c.949_c.971 
(Exon 11q) 
CTTCCAGCCCATCTGTTATGTTG 389 433 466 510 531 
E8.1-E12 
c.459_c.478 
(Exon 8) 
TGTCCAACTCTCTAACCTTG 
c.4145_c.4164 
(Exon 12) 
CTGAGAGGATAGCCCTGAGC 276b 320b 353b 397b 418b 
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1. 3 Digital PCR (dPCR) 
All dPCR experiments were performed in a QuantStudio 3D Digital PCR 20K platform 
according to the manufacturer’s instructions (Applied Biosystems, Foster City, CA). As 
indicated, we performed different assays combining FAM-labeled and VIC-labeled TaqMan 
assays. FAM-labeled assays included an Applied Biosystem pre-designed assay 
(Hs01556198) specific for the E8/E11 junction (9,10 assay), and a custom designed TaqMan 
assay specific for the BRCA1 E9/E10 junction (FL assay). The FL assay was designed with 
the Applied Biosystem proprietary on-line pipeline.   VIC-labeled assays included an Applied 
Biosystem pre-designed assay (Hs01556193) specific for BRCA1 E23/24 junction (a proxy for 
overall BRCA1 expression), and  a pre-designed assay (Hs00609073) specific for BRCA2 
E26/27 junction (a proxy for overall BRCA2 expression). dPCR chips were analyzed in the 
cloud-based QuantStudio 3D Analysis Suit v2.0 (Applied Biosystem, Foster City, CA) to 
review quality (only green and yellow flag chips were considered for further analyses), and 
calculate copies/µl of FAM and VIC molecules (and the precision of these measures). Default 
settings were used in all cases. Subsequently, data was exported to an excel file to calculate 
the FAM/VIC ratio. To measure 9,10SF, we performed experiments combining 9,10 and 
Hs01556193 assays. To measure FL
SF
 we performed experiments combining FL and 
Hs01556193 assays. To measure 9,10 and FL relative expression levels, we performed 
experiments combining 9,10 (or FL) assays with Hs00609073. In relative expression level 
experiments, the 9,10 (or FL) relative expression level of each sample was normalized to the 
average 9,10 (or FL) relative expression level as measured in control samples. 
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1.4 Absolute quantification of alternative splicing events by real-time PCR (qPCR) 
In order to specifically amplify BRCA1 full-length transcripts (transcripts containing exons 
9,10, and 11q), transcripts containing six naturally occurring alternative splicing events (∆9, 
9,10, 9_11, ∆10, ∆11, and ∆11q), or transcripts combining two splicing events 
(9,10+∆11q), we designed various primers in specific exonic regions, or overlapping 
specific exon/exon junctions. Specificity of primer combinations (we tested 3 primer sets 
peralternative splicing event ) were determined by temperature gradient PCR. Pooled cDNA 
from healthy controls was used as template to amplify all specific alternative splicing event 
fragments, with the single exception of ∆10 fragments, which were obtained using variant 
carrier cDNA as template.  Cycling conditions were 95°C for 2mins followed by 35 cycles of 
95°C for 30secs, gradient annealing temperature (annealing temperature of 55°C - 65°C at 
intervals of 2°C) for 30secs, 72°C for 60secs and a final extension time of 7mins. Gel 
electrophoresis was used to visualize the fragments. PCR products amplified using a primer 
combination and lowest annealing temperature for which only one PCR product could be 
observed were considered optimal (see table at the end of this section) and selected for 
cloning.  PCR products were cloned using the pGEM-T Vector System (Promega, Auburn, 
Victoria, Australia). Recombinant clones were selected from a single colony and sequence 
confirmed. Plasmid preparations containing the PCR products for each of the eight fragments 
were quantified using a Qubit 3.0 Fluorometer (Aplied Biosystems, Foster City, CA) and a 
serial dilution was made. Dilutions were used as template for deriving a standard curve for 
quantitative PCR (qPCR).  
A standard curve was determined using pGEM-T clones carrying the eight isoforms and the 
specific primers/annealing temperature for each transcript. Real-time PCR reactions were 
carried out in a Lightcycler 480 (Roche, Castle Hill, NSW, Australia) using Platinum SYBR 
Green qPCR SuperMix-UDG (Invitrogen). Cycling conditions were: 50°C for 2mins, 45 
cycles of 95°C for 2mins, 95°C for 20secs, optimized annealing temp (see table at the end of 
this section)15secs, 72°C for 20secs.     Normalized expression values (using GAPDH as an 
internal reference) were obtained using the Lightcycler 480 Gene Scanning software for 
cDNA isolated from the variant carrier and a set of 11 non-variant carrying controls. Crossing 
point (CP) values were plotted against the standard curve. The number of molecules of the 
3.2Kb plasmid was estimated at 2.9x10
8
/ng. Given that there are approximately 290 million 
molecules in 1ng plasmid, the starting number of molecules in each reaction could be 
estimated enabling a comparison within a sample and across the controls. 
6 
 
 
 
 
 Table 2. Optimal primer sequences and annealing temperatures for absolute quantification of alternative splicing eventsby qPCR 
  
 
 Forward Reverse product (bp) Annealing Temp (Cº) 
Full-length ex10F CTCAAGGAACCAGGGATGAA ex11pR ACTGGGTTGATGATGTTCAGT 101 63 
∆11 ex10/12F TGGATTCTGCAAAAAAGGGTGAA ex12R CTGAGTGGTTAAAATGTCACTCTGA 107 61 
∆11q ex11p/12F ATCCAGAAAAGTATCAGGGTGAA ex12R CTGAGTGGTTAAAATGTCACTCTGA 107 59 
∆9_11 ex8/12F TGTCTACATTGAATTGGGTGAAGCA ex12R CTGAGTGGTTAAAATGTCACTCTGA 106 63 
∆9,10 ex8/11F TGTCTACATTGAATTGGCTGCTTGT ex11pR GCACGCTTCTCAGTGGTGT 101 65 
∆10 ex9/11F AATAAGGCAACTTATTGCAGCTGCTTGT ex11pR GCACGCTTCTCAGTGGTGT 104 61 
∆9 ex8/10F GTCTGTCTACATTGAATTGGTGTGG ex10/11R CTCAGAAAATTCACAAGCAGCCTTT 113 61 
∆9,10+∆11q ex8/11pF TCTGTCTACATTGAATTGGCTGCTT ex11p/12R AGATGCTGCTTCACCCTGAT 146 61 
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1.5 RNAseq experiments. 
The TruSeq targeted RNA expression kit (Illumina, San Diego, CA) was used to target exon 
regions across BRCA1. Each probe pair targets a specific splice junction or coding SNP. 
Coding SNP probes are situated within the same exon, either side of the variant of interest, 
whereas splice junction probes are positioned near the 3’ and 5’ end of two adjacent exons, 
respectively. This design allows for the detection of certain alternative splicing events, and 
small splice junction aberrations, as the probes do not need to bind specifically with the other 
in their original pair. Any exon skipping event has the potential to be detected providing there 
is an upstream and a downstream probe flanking the deletion. Briefly, TruSeq Targeted RNA 
Expression chemistry involves pre-designed oligonucleotide probes that hybridise to the 
target BRCA1 cDNA region followed by an extension-ligation reaction then takes place to 
connect the probes, and an amplification step to create the template strand. This is PCR 
amplified to add indices prior to sequencing. Sequencing was performed on Illuminas MiSeq 
platform. All BRCA1 exons had predesigned probes situated on either end to allow detection 
of non-aberrant mRNA splice junctions, with the single exception of BRCA1 16-17. In 
addition, one probe in the BRCA1 3-5 pair spans the splice site inhibiting detection of splicing 
events involving this junction. TruSeq targeted RNA expression kit allowed us to also 
quantify each detected splice junction. After normalizing the read counts, the expression of 
each splicing event was compared across samples to determine expression differences. All 
samples were sequenced with and without treatment of Cycloheximide. 
Splice junction BRCA1 2-3 was used as the full length reference transcript. We assumed that 
this junction is present in all alternative splicing events that don't overlap this junction. We 
also assumed that the alternative events do not co-occur. Under these assumptions we 
subtracted all alternative splicing reads, that didn't overlap the exon 2-3 junction, from the 
total 2-3 junction reads. Some junctions were exempt from this as they are common 
NAGNAG events (8p, 13p, 14p), which are likely to be present in the full length transcript. 
9,10 was also excluded as it returned questionable read depths.  
 
The resulting 2-3 read depth, together with the sum of all alternative events(excluding those 
mentioned above), gave the total expression, from which the proportions of each alternative 
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event were determined for each sample.The resulting proportions were back transformed 
(95% CI) for the log data. This provided the standard deviation and mean for the expression 
of the control samples for each junction, onto which the variant sample relative expression 
was overlayed. Delta 10 and FL data was extracted for the figures 
 
1.6 RNA interference experiments.  
All small interference RNAs (siRNAs) used represent validated sequences in several previous 
publications from our and other labs (6). 25 nM final concentration of A1 (hnRNP A1) siRNA 
(5’-CAGCUGAGGAAGCUCUUCAdTdT-3’), Tra2 siRNA (5’-
GCAUGAAGACUUUCUGAAAdTdT-3’), SF2 (SRSF1) siRNA (5’-
CCAAGGACAUUGAGGACGUdTdT-3’), or SC35 (SRSF2) siRNA (5’-
AAUCCAGGUCGCGAUCGAAdTdT-3’) were transfected into MDAMD231 cells with 
INTERFERin (Polyplus transfections, Illkirch, France) following the manufacturer’s 
instructions. As a control, we transfected a scrambled sequence (the luciferase siRNA 5’-
CGUACGCGGAAUACUUCGAdTdT-3). Forty-eight hours later, the RNA was extracted 
using RNAeasy plus kit (Qiagen, Hilden, Germany). The overall strategy has been described 
previously (6). 
 
1.7 In silico predictions of variant-induced alterations in Exonic Splicing Regulatory 
sequences (ESRseq)  
We analyzed the potential impact of BRCA1 c.641A>G on RNA splicing by using an in silico 
approach based on the calculation of total ESRseq score changes (ΔtESRseq) as described 
previously (7). 
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1.8 Splicing Reporter Minigene Experiments 
pCAS2-BRCA1-exon 10 minigene assay 
The pCAS2 splicing vector has been previously described (8). The pCAS2-BRCA1-exon-10 
minigene constructs (Figue 3A) were generated as follows. First, the wild-type genomic 
segment BRCA1 c.594-147_c.670+173 was amplified by PCR from genomic DNA using 
forward primer BR1-10-BamHI-F (GACCGGATCCCTAAAGGAGAGAG) and reverse 
primer BR1-10-MluI-R (GACCACGCGTTTTAAATCTATCAG), carrying 5’ tails with 
BamHI and MluI restriction sites, respectively (underlined). PCR-amplified genomic 
segments encompassed BRCA1 exon 10 (77 bp) and part of the 5’ and 3’ flanking intronic 
sequences (147 bp  and 173 bp, respectively). After digestion with BamHI and MluI, the PCR 
products were inserted into the BamHI and MluI cloning sites of pCAS2, a two-exon splicing 
reporter vector, in order to produce the three-exon pCAS2-BRCA1-exon10-WT minigene. 
Then, variants of interest were introduced into this construct by site-directed mutagenesis 
using the two-stage overlap extension PCR method (9). The inserts of the mutant minigenes 
were sequenced to ensure that no unwanted mutations were introduced during amplification 
or cloning. 
Wild-type and variant minigene constructs were transiently transfected in parallel into HeLa 
cells using the FuGENE 6 transfection reagent, according to manufacturer’s instructions 
(Roche Applied Science, Mannheim, Germany). Transfections were performed in 12-well 
plates by using 6x10
4
 cells/well (at ~60% confluence) and 400 ng of each minigene construct. 
Cells were then collected 24 h post-transfection. Total RNA was extracted using the 
NucleoSpin RNA II kit (Macherey Nagel, Düren, Germany), according to the manufacturer’s 
instructions, including a DNase treatment. The RT-PCR reactions were performed in a 25 µl 
reaction volume by using the OneStep RT-PCR kit (Qiagen, Hilden, Germany), and 200 ng 
RNA as template. Reactions were performed using the vector-specific forward primer pCAS-
KO1F (5’-TGACGTCGCCGCCCATCAC-3’) and the reverse primer pCAS2R (5’-
ATTGGTTGTTGAGTTGGTTGTC-3’), with 30 cycles of amplification. RT-PCR products 
were separated by electrophoresis on 2% agarose gels containing ethidium bromide and 
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visualised by exposure to ultraviolet light under conditions of non-saturating exposure. RT-
PCR products were gel-purified and fully sequenced to determine their identity. 
 
pB1 minigene assay 
The pB1 minigene splicing reporter vector has been previously described (10). This construct 
has a pcDNA3(+) backbone and contains the exon 1 of α-globin followed by BRCA1 exons 8 
to 12 (and part of their flanking intronic regions) in under the control of the CMV promoter. 
Mutant pB1 minigenes were prepared by site-directed mutagenesis  through a two-step PCR 
overlap extension method (9). After digestion with XhoI and HindIII, the BRCA1 fragments 
(c.594-174_c.670+345) containing the variants of interest were inserted into pB1 in lieu of the 
corresponding WT sequence. Then, the inserts of the mutant minigenes were sequenced to 
ensure that no unwanted mutations were introduced during amplification or cloning. Wild-
type and variant minigene constructs were transiently transfected into HeLa, MCF7, HBL100, 
and IgrOV1cells Transfection, RNA extraction and RT-PCR analysis were performed as 
described above for pCAS2-BRCA1-exon10, with the exception that the RT-PCR primers 
used here were:  pB1-V.8(2)-F (,5’-GAGGCCCTGGAGAGGACA-3‘,a vector-specific 
forward primer) and RT.1.8-11-R (, 5’-ACGCTTCTCAGTGGTGTTCA-3’, a reverse primer 
on BRCA1 exon 11).  
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Dr Anthony Wynshaw-Boris 
Executive Editor 
Human Molecular Genetics 
2016-02-10 
 
Dear Dr Wynshaw-Boris, 
Re: HMG-2015-D-01383 
 
Thank-you for the positive reviews of our manuscript entitled “Combined genetic and splicing analysis of 
BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for 
developing disease gene variant classification algorithms”. 
 
Please find below detailed responses to address the reviewer and editorial comments. 
 
Reviewer 1 
The study is well conducted, exhaustive and has important implications for diagnostics, making it 
necessary to reconsider the predicted pathogenicity of certain variants in the gene. I have only minor 
comments to be addressed. 
 
The authors provide a similar frequency of c.594-2A>C in cases and controls from 11 studies in which 
there was at least one observation of the variant. The finding of 7 and 9 heterocigotes in 24,605 and 
25,836 cases and controls respectively is considerably higher that the reported in ESP (1 heterocigote of 
4300 individuals) or ExAc (2 of of 109096 alleles counted). The authors should comment on this, 
especially regarding the slightly higher frequency found in their control population. 
While it does appear that the frequency of the c.594-2A>C variant is somewhat higher in the BCAC 
sample set than in public databases, it is impossible to say if we find too many or they find too 
few.  We also note that quite different technologies to detect this variant are used in the BCAC data 
sets than in the two reference sets. This could also explain the lack of finding it in a higher frequency 
in the ExAC/ESP data sets. Further it is clear that the frequency of this variant may be somewhat 
population/geography dependent as it was observed in a subset of the BCAC European ancestry 
populations. We have observed this for other rare variants in BRCA1 and BRCA2. Although difficult to 
know for sure, we imagine that the sub-population structure of the non-Finnish European set of ExAC 
and the ESP dataset are similar to that of BCAC. For example it appears as if there is a higher 
proportion of American samples in the public reference datasets than in the BCAC set. We would 
imagine that the population structure of the US-based samples to have a higher degree of admixture 
than say, the BCAC set from Sweden and Denmark. Finally, we must admit that these differences 
could simply be due to chance. In any case, it is difficult to see how these minor frequency differences 
could explain our findings that the c.594-2A>C variant is not a pathogenic BRCA1 variant.  
I would appreciate not to use the abbreviation “ASEV” to design an alternative splicing event. I don´t see 
the necessity of introducing a “new” term and is more confusing than helpful.  
We have removed the abbreviation. 
The discussion section is a bit long and reiterative. I would suggest making it more concise to highlight 
the important points; I don´t find it easy to follow in the present format. 
A more concise discussion (1233 words vs. 1627 in the original manuscript) has been incorporated into 
the manuscript. We have eliminated references to a “previous rescue model vs. a new recue model”, 
so that we hope now the discussion is less reiterative and easier to follow.  
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Reviewer 2 
The study is thorough and well described and evidence present supports the conclusions drawn.  
..parts of the manuscript use an overly conversational tone and some imprecise language e.g. “There 
was convincing evidence”, “The vast majority” which the authors should remove to improve readability. 
We have amended the text in response to this comment. 
 
 
Background: 
Use dbSNP IDs for both variants (rs80358033 and rs55680408) 
dbSNP IDs have been incorporated into the results section (genetic studies), and also in the new 
supplemental Figure 1 panel A. 
It would be useful to have a schematic figure to describe the position of the two variants discussed 
relative to exons 9 and 10. 
A new schematic figure has been added as Supplemental Figure 1 panel A 
Replace text “splicing aberrations and risk is not dichotomous” as is not entirely clear and (by my 
reading) suggests the opposite of what is meant. 
We have amended the text to read: “These observations indicate that the relationship between 
splicing aberrations and increased risk is not straightforward…” 
 
Results: 
p6 - replace “the vast majority” with figures e.g. 21 of 25 tumours were ER positive. 
We have replaced the text with the following: “The majority of tumors were ER positive (25/32)”. 
Another tumor was grade 1 ER status unknown (thus also contributing to odds against pathogenicity), 
and only 6 tumors were ER-negative. 
p7 - “2.77x10^6” should read “2.77x10^6:1” 
Done. 
p7 - again it would be helpful to have a schematic figure to describe the alternative splicing events being 
studied 
Done. A new schematic figure has been added as Supplemental Figure 1 panel A. 
p9 - “FL (transcripts containing” should be “FL transcripts (containing” 
Amended. 
p9 and throughout manuscript - replace “ex vivo” with “in vitro” 
Since the terminology to describe such assays may be debated, we have rather elected to remove the 
term “ex vivo”, and rather just refer to the technique as “minigene assays” without the need to 
qualify it as ex vivo or in vitro. 
Discussion: 
p11 - description of the delta9,10 rescue model is unclear - especially the use of “substituting” please 
clarify 
p12 - replace “most predominant” with “predominant” 
p12 - replace “highly predominant” with “predominant” 
As suggested by reviewer 1, we have revised the discussion section. It is now shorter and, we believe, 
easier to follow. In this new version, the term “substituting” has been eliminated, and suggested 
replacements incorporated.  
p12 - in the discussion of haplosufficiency the argument appears to be made that both the deletion 
resulting from the skipping of exons 9 and 10 and reduction of level of productive transcripts (assuming 
some degradation of delta10 transcripts by NMD) have no affect on the tumor suppressor activity of 
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BRCA1 - the evidence presented in the manuscript supports this for heterozygous cases - have any of the 
studies identified patients (or controls) homozygous for 594-2A>C;641A>G or compound heterozyotes 
with similar consequences to test this more rigorously? 
We have not identified homozygotes for BRCA1 c. 594-2A>C in our study, and would not expect to, 
given the rarity of this variant. BRCA1 c. 594-2A>C was not identified in CIMBA as a compound 
heterozygote with a pathogenic BRCA1 variant.  
 
Methods: 
p18 - replace “knock-downing” with “knocking down” 
Replaced 
 
Figure Legends: 
p25 - replace “detected as well” with “detected” 
Replaced 
p25 - why is splicing fraction (SF) expression as a percentage? Splicing percentage (or an equivalent) is 
similar to the more widely used percent spliced in (PSI) metric and would be better description 
PSI (percent Spliced In, or percent spliced in Index) is a metric developed for RNAseq data, which 
involves counting reads that align to known or predicted splice junctions, to estimate efficiency of 
splicing. It is calculated as the ratio between exon inclusion reads, and combined exon inclusion plus 
exclusion reads.  This intron-centric method estimates the incidence of single-exon-skipping events.  
While PSI metrics can be probably used for dPCR data, we believe this metric is not appropriate for 
the data variables provided by capillary EP (peak areas) or qPCR (Ct values). Since we express capillary 
EP and qPCR as splicing fraction, we prefer for the sake of internal consistency to also express dPCR 
data as splicing fraction.  Further, PSI is intended to be informative in simple situations such as 
cassette exons where only two splicing events (exclusion/inclusion) are possible. In our study, the 
situation is far more complex, with up to five different splicing events competing. Just one example, 
exon 9 inclusion can reflect up to 3 different transcripts (full-length, delta10, and ins10p), and exon 9 
exclusion can reflect up to 2 different transcripts (delta10 and delta9,10). For that reason, exon9 
inclusion/exclusion rate is not very informative.  
p27 - replace “with the only exception” with “with the exception” 
Replaced 
p28 - remove “notoriously” 
Removed 
p28 - replace “events are highlighted in red” with “events are highlighted with a red cross” 
Replaced 
p29 - remove “last but not least” 
Removed 
 
Figures: 
fig 1 - missing Y-axis labels in panel A 
We have included a Y-axis label (fAU, fluorescence intensity in arbitrary units), and described this in 
the figure legend.  
fig 3 - inconsistency in cell-line name - IGROV1 in main text and legend - IgOv1 in panel B label 
Amended - now IGROV-1 both in text and legend. 
 
Supplemental Methods: 
p1 - “different commercially available kits” - please include details 
Now we have included details as follows: “For RT-PCR reactions, different contributors used different 
commercially available kits (SuperScriptII Reverse Transcriptase, Invitrogen, Carlsbas, CA; High 
Capacity RNA-to-cDNA Mater Mix, Applied Biosystems, Foster City, CA; Primescript RT reagent kit, 
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Takara Biotechnology, Shiga, Japan; Transcriptor High Fidelity cDNA synthesis Kit, Roche Applied 
Science, Mannheim, Germany; One-Step RT-PCR kit, Qiagen, Hilden, Germany) in combination with 
oligodT and/or random hexamers.” 
p2 - “various ABIPRIS Genetic Analyzers” - please include details 
Now we have included details as follows: “Depending on the contributing laboratory, capillary 
electrophoresis analyses were performed with 3100, 3130, 3130XL, 3500XL, or 3730XL ABI PRISM 
Genetic Analyzers (Applied Biosystems, Foster City, CA) using POP-7 filled capillary arrays of 36 or 50 
cm. Size-calling and peak areas were analyzed with GeneMapper v4.0 or GenScan v3.7 software (both 
from Applied Biosystems, Foster City, CA), or GeneMarker 2.4 (Softgenetics LLC, State College, PA). As 
internal size-standard, we used LIZ-500 or LIZ-1000 (Applied Biosystems, Foster City, CA).” 
Table 1 - reduce font size as text wrapping makes expected peak sizes confusing to read 
Done 
 
Supplemental Data: 
p2 - colours and shadow on graph make it difficult to read text - please modify to use light shades and 
remove shadow 
Modified. In addition, we have modified a similar graph in Figure 4 for consistency.  
p3 - Panel A Carrier 8 - although this sample is not reported to include Puromycin or Cyclohexamide the 
delta10 SF is as high as all Puro+ and Cyclo+ samples - is this a missing label or genuinely high expression 
in Puro/Cyclo- sample - in which case it would be worth remarking on in text. 
Carrier 8 corresponds to RNA extracted from fresh blood directly collected in tubes containing a RNA 
preserving solution (PAXgene tubes, Qiagen), hence not involving cell culture/puromycin treatment. 
Therefore, we conclude that our data represents genuinely high expression of delta10 in this 
particular sample. We have now specifically remarked on this fact in the text corresponding to 
supplemental figure 2 as follows:  “one fresh blood sample (PAXgene system for blood sampling, no 
puromycin/cycloheximide treatment) named Carrier 8, and its corresponding control. Note the high 
level of ∆10 transcripts in Carrier 8, despite the fact that NMD is not inhibited by the PAXgene 
system” 
Further, thanks to the reviewer comment, we realized that there was a minor error related with the 
Carrier 8 boxplot (related with data input into the SPSS data editor). This error has now has been 
fixed, and compared with the previous version of the box plot:  
1) delta10 expression in the carrier is now slightly lower (36% vs. 39%), and  
2) it is now apparent that the data corresponding to the 3 control samples is very similar, but not 
identical.   
These corrections do not affect at all the interpretation of results.  
 
Editorial and formatting changes: 
TITLE PAGE: 
___Complete author names (first name, middle initial, (if required) and last name) should be listed 
separately from their institutions/affiliations. Use numbers to reference one to the other. Do not use 
academic degrees (i.e. MD, PhD, MSc). 
Compliant 
___The corresponding author should be designated with an asterisk (*). Address, telephone, FAX, and 
email address should be listed. The publisher allows only one corresponding author. 
We have replaced the superscript number with an asterisk. We ask respectfully for deviation of 
publishing restrictions to one corresponding author for this paper spanning splicing and genetics, 
since we think that the combined expertise of the two proposed corresponding authors will facilitate 
our ability to respond in most informative manner to questions arising from this publication. 
___Financial/funding information should be listed in the acknowledgement section. 
Amended 
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MANUSCRIPT: 
___The section sequence order should be: Title Page, Abstract, Introduction, Results, Discussion, 
Materials and Methods, Acknowledgements, Conflict of Interest Statement, References, Legends to 
Figures, Tables and, finally, Abbreviations. Figures should be saved as separate high-resolution image 
files. Abbreviations are used for copy-editing purposes only. 
Amended 
___Running title, key words, word count, figure and/or table count should be deleted from the 
manuscript. The journal does not publish this information. 
Compliant 
___Use TIMES NEW ROMAN font for all text. 
Amended 
___Double-space the text. 
Amended 
 
 
REFERENCES: 
___Type complete page numbers i.e. 345-349 NOT 345-9 or 345-49. 
___Punctuate ALL abbreviated words in journal titles, i.e. Hum. Mol. Genet. NOT Hum Mol Genet. 
___Abbreviate journal titles. 
___Italicize journal titles. 
___Volume number should be keyed in boldface. 
___Do not use issue numbers. 
___List 10 authors before adding et al. 
___Use proper spacing between author names and initials. 
___Use commas (,) not colons (:) in the references. 
___Article titles of references are required. 
Amended where relevant. Please note some journals do not provide page numbers, but rather e-
references. 
 
 
SUPPLEMENTAL DATA: 
___Supplemental data should be uploaded in a separate fil  from that of the main manuscript. 
Compliant 
 
FIGURES 
The four figures are provided in TIFF format with the proper size and dpi 
 
We hope these responses and edits meet with your approval. For the main text, we have provided a 
document with changes tracked/noted, and another clean document. We have also uploaded scans of 
two conflict of interest statements, relevant to this manuscript. 
 
Sincerely 
Amanda Spurdle and Miguel de la Hoya 
Corresponding authors 
Amanda.Spurdle@qimrberghofer.edu.au; mdhoya@hotmail.com 
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Abstract 
A recent analysis using family history weighting and co-observation classification modeling indicated that 
BRCA1 c.594-2A>C (IVS9-2A>C), previously described to cause exon 10 skipping (a truncating 
alteration), displays characteristics inconsistent with those of a high risk pathogenic BRCA1 variant. We 
used large-scale genetic and clinical resources from the ENIGMA, CIMBA and BCAC consortia to assess 
pathogenicity of c.594-2A>C. The combined odds for causality considering case-control, segregation, and 
breast tumor pathology information was 3.23x10
-8
. Our data indicate that c.594-2A>C is always in cis 
with c.641A>G. 
The spliceogenic effect of c.[594-2A>C;641A>G] was characterized using RNA analysis of human 
samples and splicing minigenes. As expected, c.[594-2A>C; 641A>G] caused exon 10 skipping, albeit 
not due to c.594-2A>C impairing the acceptor site but rather by c.641A>G modifying exon 10 splicing 
regulatory element(s). Multiple blood-based RNA assays indicated that the variant allele did not produce 
detectable levels of full-length transcripts, with a per allele BRCA1 expression profile comprised of ≈70-
80% truncating transcripts, and ≈20-30% of in-frame ∆9,10 transcripts predicted to encode a BRCA1 
protein with tumor suppression function. 
We confirm that BRCA1c.[594-2A>C;641A>G] should not be considered a high-risk pathogenic variant. 
Importantly, results from our detailed mRNA analysis suggest that BRCA-associated cancer risk is likely 
not markedly increased for individuals who carry a truncating variant in BRCA1 exons 9 or 10, or any 
other BRCA1 allele that permits 20-30% of tumor suppressor function. More generally, our findings 
highlight the importance of assessing naturally occurring alternative splicing for clinical evaluation of 
variants in disease-causing genes. 
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Introduction 
Sequence variants that alter the highly conserved intronic dinucleotides at splice donor and acceptor sites 
of high-risk disease predisposition genes are often assumed to be pathogenic, due to their high likelihood 
to alter RNA splicing. Although such variants will almost certainly lead to disruption of normal splicing 
patterns, the exact nature of the resulting alternate splicing patterns cannot be reliably predicted.  Indeed, 
a standardized classification scheme recently developed for mismatch repair gene variants through 
consensus across multiple international sites (1) proposes that mRNA assay and/or clinical data are 
necessary to upgrade dinucleotide donor and acceptor variant classification from “likely pathogenic” to 
“pathogenic”.  
The dinucleotide acceptor site variant BRCA1 c.594-2A>C (also known as IVS9-2A>C) has recently been 
reported associated with clinical characteristics inconsistent with a high risk of cancer expected for a 
pathogenic BRCA1 variant (2). Previous RNA analyses of carriers of BRCA1 c.594-2A>C indicate that 
this variant is associated with an aberrant mRNA profile (3, 4), including production of exon 10 deleted 
out-of-frame transcripts. These observations indicate that the relationship between splicing aberrations 
and increased risk is not straightforward, and pose the question of which measures of mRNA transcript 
dysregulation best reflect variant pathogenicity, considering recommendations already published by the 
ENIGMA Splicing Working Group (5).  We undertook a study to assess level of risk associated with 
BRCA1 c.594-2A>C using segregation and large-scale case-control analysis, and detailed mRNA analyses 
correlating genotype with aberrant mRNA profiles.  
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Results 
Genetic studies 
Characteristics of BRCA1 c.594-2A>C variant carriers identified in BCAC, CIMBA, and ENIGMA are 
detailed in Supplementary Tables 1 and 2.  
BRCA1 c.594-2A>C (rs80358033) was identified in 7/24,605 invasive breast cancer cases and 9/25,836 
controls, when including only the 11 studies with at least one observation (Supplementary Table 1). 
Standard case-control analysis yielded an odds ratio (OR) of 0.82 (95% CI 0.26-2.47), which was little 
different after adjustment for principle components (OR 0.83, 95% CI 0.41-2.24).  However, some studies 
indicated that they had performed BRCA1/2 mutation screening of cases and may have excluded cases 
with pathogenic variants.  Since BRCA1 c.594-2A>C has generally been assumed to be pathogenic on the 
basis of its location at a splice acceptor site, this could create a bias due to preferential exclusion of c.594-
2A>C carriers cases but not controls. After exclusion of four studies that did such genetic testing, we 
were left with 5/20,992 cases and 6/22,332 controls that carried the c.594-2A>C variant (See 
Supplementary Table 1), yielding a revised OR of 0.87 (95% CI 0.26-2.86) after adjustment for principle 
components.  The odds for causality based on carrier frequency and ages at diagnosis/interview in these 
cases and controls was 7.3 x 10
-5
 (equating to an odds against pathogenicity of 13770:1). The case-control 
findings demonstrate that the BRCA1 c.594-2A>C variant is clearly not associated with a high risk of 
breast cancer, and is unlikely to be associated with even a moderate (~3-5-fold) risk of breast cancer. 
There were 15 BRCA1 c.594-2A>C carrier individuals from 13 families identified in the CIMBA dataset 
through genotyping with the iCOGS array. It was confirmed with the submitting sites that none of these 
individuals carried another pathogenic variant in BRCA1, and that 8 of these families overlapped with 
those identified via ENIGMA while the proband for another family was also recruited into BCAC. 
Overall, information for segregation analysis was available for 14 probands from ENIGMA/CIMBA 
(Supplementary Table 1), and breast tumor pathology information for 32 cases from ENIGMA, CIMBA 
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or BCAC (Supplementary Tables 1 and 2). The combined odds for causality based on segregation 
analysis, assuming BRCA1 age-specific risks of breast and ovarian cancer as estimated in the large study 
of Antoniou et al (6), was 0.10 (ranging from 0.02 to 6.85 for individual families). The breast tumor 
pathology features of variant carriers were not consistent with those found commonly for high-risk 
BRCA1 pathogenic variant carriers. The majority of tumors were ER positive (25/32), and the odds for 
causality based on pathology information was 4.98x10
-6
 (200994:1 against causality). 
After contacting the submitting centres and through re-investigation of original genetic test results, the 
BRCA1 exonic variant rs55680408 (c.641A>G, p.Asp214Gly) was confirmed to be present in all 
ENIGMA/CIMBA c.594-2A>C families included in the final analysis, and another 13 c.594-2A>C 
carriers identified by Ambry Genetics that were excluded from analysis due to lack of relevant clinical 
information. Specifically, review of genetic testing data by Ambry Genetics identified a total of 20 
carriers of BRCA1 c.[594-2A>C; 641A>G] from >213,000 tests, including two siblings and a mother-
daughter pair; there was clear evidence that the alleles were in cis from next generation sequencing reads, 
and neither allele was observed alone in 2636 unrelated parent exomes. Further, all carrier individuals 
from BCAC were shown to share the same BRCA1 haplotype (data not shown). Based on the haplotype 
and genotype information, it was assumed that all BRCA1 c.594-2A>C carriers in the BCAC dataset were 
also carriers of c.641A>G (p.Asp214Gly). Considering case-control, segregation and pathology 
information, the combined odds for causality was 3.61x10
-11
 (i.e. 2.77x10
10
:1 against causality). These 
results indicate that individuals carrying BRCA1c.[594-2A>C; 641A>G] (Supplemental Figure 1A) 
should be counselled as not having a high risk of BRCA1-associated disease. 
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Splicing studies 
 
Comprehensive characterization of BRCA1 alternative splicing landscape in c.[594-2A>C; 641 A>G] 
carriers by capillary electrophoresis and high throughput RNA sequencing (RNAseq).  
 
To search for a plausible biological mechanism explaining the lack of evidence for an increased cancer 
risk in BRCA1 c.[594-2A>C; 641A>G] carriers, we first performed a comprehensive characterization of 
the BRCA1 alternative splicing landscape in the vicinity of exon 10.With this aim, we performed a series 
of capillary electrophoresis analyses on RNAs obtained from lymphoblastoid cell lines (LCLs) (see 
methods). We have shown previously that this approach is highly sensitive, allowing comprehensive 
identification, characterization, and semi-quantification of alternative splicing (4, 7). Experiments 
performed with two combinations of forward and reverse primers located in exons 8 and 11detected up to 
five different alternative splicing events both in LCLs from one c.[594-2A>C; 641 A>G] carrier (Carrier 
1) and healthy controls (Figure 1), including 3 in-frame (full-length (FL), ∆9,10, and ▼10p), and two out-
of-frame  (∆9 and ∆10). All but ▼10p (r.594-21_594-1ins) have been described previously as naturally 
occurring BRCA1 alternative splicing events in control samples (7). No c.[594-2A>C; 641A>G] specific 
events were identified. Overall, experiments conducted in the presence of puromycin (Puro+ experiments 
in Figure 1 and Supplemental Figure 1) indicated that ∆9,10 splicing fraction (∆9,10
SF
) is similar in 
Carrier 1 and Controls (≈29%), ∆10
SF 
is considerably higher (≈38% vs. ≈1%), and FL
SF 
much lower 
(≈31% vs. ≈66%). ∆9
SF 
(<3%) and ▼10p
SF 
(<1%)were rather minor alternative splicing events in all 
tested samples. As expected, Puro- experiments measured higher ∆9,10
SF 
in Carrier 1 than in Controls 
(Figure 1A and Supplemental Figure 1) due to a drop in ∆10
SF
, probably reflecting nonsense mediated 
decay (NMD) degradation of out-of-frame ∆10 transcripts. 
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Overall, findings were confirmed by comparable experiments performed by other contributing centers 
(Supplemental Figure 2), assaying up to eight individual variant allele carriers identified in four unrelated 
families and 3 different types of samples (LCLs, Leukocytes (LEUs), and fresh whole blood); there was 
similar ∆9,10
SF 
in Carriers and Controls (range 20-30% depending on specific protocols and/or sample 
used for experiments), and a significant increase of ∆10
SF 
(with corresponding decrease of FL
SF
) in 
Carriers. Complementary analyses performed in the subpopulation of BRCA1∆11q transcripts were 
coincident, with similar (∆9,10+∆11q)
SF 
 in Carriers and Controls, and a significant increase of  
(∆10+∆11q)
SF 
(with corresponding decrease of ∆11q
SF
) in Carriers (Supplemental Figure 2C). 
Incidentally, our data supports ▼10p as a naturally occurring BRCA1 alternative splicing event not 
previously reported, probably due to its very low SF. Capillary electrophoresis findings (in particular the 
lack of variant allele specific transcripts, and the detection of ▼10p in Controls) were confirmed by 
RNA-seq experiments (Supplemental Figure 3). 
 
 
Quantitative analyses combined with alternative splicing event specific biallelic expression analyses 
confirms that c.[594-2A>C; 641A>G] modifies the BRCA1 alternative splicing landscape, but not the 
overall BRCA1 expression level.  
 
The comprehensive analysis of the BRCA1 alternative splicing landscape described above did not provide 
an obvious explanation for why c.[594-2A>C; 641A>G] carriers do not display features of a standard 
pathogenic BRCA1 variant. Yet, the absence of carrier-specific transcripts prompted us to speculate that it 
is perhaps the actual level of naturally occurring in-frame transcripts in variant allele carriers that may 
explain the genetic findings, in particular levels of FL and ∆9,10 transcripts given that▼10p transcript 
levels were very low. Since capillary electrophoresis is a semi-quantitative approach, we decided to 
perform further analyses with quantitative PCR (qPCR) and digital PCR (dPCR) that, overall, confirmed 
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capillary electrophoresis findings (Figure 2). qPCR absolute quantification of individual alternative 
splicing events in Carrier 1 estimated for ∆9,10
SF
 a value of 19%±0.9, in the upper-limit of Controls 
(ranging from 4% to 17%)(Figure 2A, left), together with an obvious reduction of FL transcripts (Figure 
2A, right). In addition to ∆9,10, three other naturally occurring in-frame alternative splicing events 
involving exon 10 and/or nearby exon 11 have been described, namely ∆9_11, ∆11, and ∆11q (7). We 
used qPCR absolute quantification to estimate the SF of these alternative splicing events, detecting an 
increase of (∆9,10+∆11q)
SF 
in Carrier 1 (9%±0.8) if compared with Controls (average of 7%). No 
differences were observed with regard to ∆11
SF
 and ∆9_11
SF 
(Supplemental Figure 4). Similarly, dPCR 
analyses (Figure 2B) revealed a modest increase of ∆9,10
SF 
in Carrier 1 (24%±0.9) if compared with 
Controls (average of 17%), together with a 50% reduction of FL
SF 
that is fully compatible with lack of FL 
transcripts arising from the variant allele.  
 
Alternative splicing event specific reverse transcription and PCR amplification (RT-PCR) sequencing 
experiments (Supplemental Figure 5) performed in carriers 3 to 5 (from one Dutch family) confirmed that 
∆9,10 expression is biallelic, whereas ∆10 expression is essentially monoallelic (arising from the variant 
allele). Neither qPCR absolute quantification (Supplemental Figure 4A), nor biallelic expression analysis 
(Supplemental Figure 5B) suggested higher overall BRCA1expression level in c.[594-2A>C; 641A>G] 
carriers. Yet, to further exclude this possibility we performed dPCR analyses of BRCA1∆9,10 and FL 
expression relative to BRCA2 (Supplemental Figure 6). The data indicated that ∆9,10 relative expression 
level is similar in LCLs from Carrier 1 and Controls, while FL expression level shows a 50% reduction, 
again supporting that the variant allele is not producing FL transcripts.   
 
Taken together, capillary electrophoresis analyses of RT-PCR products, RNAseq, qPCR, dPCR and 
alternative splicing event specific sequencing experiments supported a model in which the variant allele 
does not produce novel BRCA1 transcripts, nor increases overall BRCA1expression level, but rather 
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substitutes FL transcripts (containing exons 9 and 10) with out-of-frame ∆10 transcripts, such that the 
contribution of in-frame ∆9,10 transcripts to the overall expression level is similar or slightly higher (see 
Figure 2, Supplemental Figure 2) to that observed in wild-type (WT) alleles. Of note, according to our 
data the overall model is also probably true in the subset of BRCA1∆11q transcripts (see Supplemental 
Figures 2C and 4B). According to this model, BRCA1∆9 (out-of-frame) and BRCA1 ▼10p (in-frame) 
contribution to the overall expression level are very low both in variant and WT alleles (see Figure 2B and 
2C), and hence irrelevant to explain the lack of risk observed in variant allele carriers.  
 
 
Splicing reporter minigene analyses reveal that c.641A>G is causing exon 10 skipping in c.[594-2A>C; 
641 A>G] carriers. 
We also performed minigene assay experiments to dissect the contribution of the individual variants 
c.594-2A>C and c.641A>G to the splicing pattern observed in variant allele carriers. Experiments were 
performed with two minigene assays (pCAS2-BRCA1-Exon10, and pB1). A schematic representation of 
these reporter minigenes is shown in Figure 3. pCAS2-BRCA1-Exon10 and pB1 experiments performed 
in HeLa cells, as well as pB1 experiments performed in breast (MCF7 and HBL100) and ovarian 
(IGROV-1) cell lines, revealed that both c.594-2A>C and c.641A>G impair normal exon 10 splicing, 
albeit with different outcomes (Figure 3). pCAS2-BRCA1-Exon10 c.594-2A>C and pB1 c.594-2A>C 
predominantly produced▼10p transcripts, but also a minor amount of ∆10 transcripts (Figure 3A), a 
finding confirming previous pSPL3-BRCA1-Exon10 experiments performed in COS-7 cells (8). By 
contrast, pCAS2-BRCA1-Exon10 c.641A>G and pB1 c.641A>G mostly produced ∆10 but no 
detectable▼10p. The finding that c.641A>G causes exon 10 skipping albeit being located outside the 
splice site, suggests that this variant disturbs the regulation of exon 10 splicing, probably by destroying 
splicing enhancer elements and/or by creating splicing silencer elements, a hypothesis supported by an in 
silico analysis based on ESRseq scores (Supplemental Figure 7A). The presence of regulatory 
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mechanisms underlying BRCA1 exon 10 splicing was further supported by small interfering RNA 
(siRNA) experiments performed in MDA-MB231 cells showing that endogenous BRCA1 depends on 
Tra2-β for exon 10 inclusion (Supplemental Figure 7B). Double mutant pCAS2-BRCA1-Exon10 c.[594-
2A>C; 641 A>G] and pB1 c.[594-2A>C; 641 A>G] experiments mimicking the variant allele observed in 
vivo produced detectable levels of both ∆10 and ▼10p, with ∆10 being the predominant outcome in all 
cell lines tested (Figure 3).  
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Discussion 
In the present study we have demonstrated that c.[594-2A>C; 641A>G] carriers (but not necessarily 
carriers of a potential BRCA1 allele in which c.594-2A>C is not linked to c.641A>G) should not be 
considered at high-risk of developing BRCA1-associated cancers. The finding is remarkable, since the 
variant allele causes exon 10 skipping, a frame-shift alteration. In addition, we propose a plausible 
biological mechanism underlying the finding, the so-called BRCA1 ∆9,10 rescue model, and we show the 
relevance of the findings for developing disease gene variant classification algorithms.  
 
The first study addressing the spliceogenic impact of BRCA1c.594-2A>C demonstrated an association 
with exon 10 skipping (3), supporting the initial pathogenic classification by Myriad Genetics (2). Here 
we confirm exon 10 skipping in c.594-2A>C carriers, and we show that contrary to expectations this 
splicing alteration is not driven by c.594-2A>C, but rather by the linked variant c.641A>G. Further, we 
show that the variant allele does not produce full-length (FL) transcripts, nor other in-frame transcripts 
apart from normal levels of ∆9,10 and residual levels of ▼10p transcripts. These findings lead us to 
conclude that ∆9,10 transcripts arising from the variant allele confer sufficient tumor suppressor activity 
in vivo  to compensate for the lack of FL transcripts.  To be more precise, the combined genetic and 
splicing data lead us to formulate a ∆9,10 rescue model in which BRCA1 alleles with an associated 
∆9,10
SF 
of ≈20%-30% (as measured in blood related samples) confer tumor suppressor haplosufficiency 
(Figure 4). The actual value is probably closer to 20% than to 30% (according both to qPCR and dPCR 
estimations in Carrier 1, and to capillary electrophoresis estimations in Carriers 2 to 8), but at any rate is 
very similar to that observed in control samples. The finding that ∆9,10 is a predominant alternative 
splicing event not only in blood derived samples but also in clinically relevant tissues such as breast and 
ovary (Supplemental Figure 8) is critical to support our rescue model for both breast and ovarian cancer. 
Indeed, family history of breast and/or ovarian cancer is a key criterion for genetic testing for most 
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participating ENIGMA and CIMBA sites, and segregation analysis modelled both breast and ovarian 
cancer risk, providing  no indication that BRCA1 c.594-2A>C (IVS9-2A>C) could be associated with 
increased ovarian cancer risk only. Further, similar to our findings reported for breast cancer, case-control 
data from a parallel study by the Ovarian Cancer Association Consortium does not support an association 
with ovarian cancer risk, with BRCA1 c.594-2A>C identified in 2/16,121 cases and 4/26,167 controls 
(OCAC, unpublished data). Note that the BRCA1 ∆9,10 rescue model predicts lack of breast and ovarian 
cancer risk not only for BRCA1 variants causing exon 10 skipping (or exon 9 skipping), but to any loss-
of-function mutation in exons 9 or 10 (nonsense or frame shift mutations), provided that the mutant allele 
produces normal levels of ∆9,10 transcripts (Figure 4).  
Evidently, the BRCA1 ∆9,10 rescue model presumes that ∆9,10 transcripts encode a protein isoform 
(BRCA1
p.Gly183_Lys223del
) that has tumor suppressor activity. To our knowledge, this BRCA1 isoform 
(lacking only 41 out of 1863 amino acid residues) has not been detected in vivo, nor functionally 
characterized in vitro, but tumor suppressor activity is fully compatible with structural considerations: 1) 
the 41 missing residues are unlikely to affect protein folding, since they are embedded in an intrinsically 
disordered protein region spanning amino acids 170-1649 (9);  2) BRCA1
Gly183_Lys223del 
includes all known 
functional domains/residues critical for tumor suppression, including the RING domain (spanning amino 
acids 2-103) that mediates binding to BARD1, an obligated heterodimer partner in vivo (10). 
Interestingly, BRCA1
p.Gly183_Lys223del 
lacks some residues critical for E3 ligase activity (11), a BRCA1 
function that appears to be dispensable for tumor suppression (12, 13). Yet, the most compelling 
argument supporting BRCA1
p.Gly183_Lys223del
 tumor suppressor activity stems from combined genetic and 
splicing analyses of BRCA1 c.591C>T (rs1799965). This variant, also not associated with the high risk of 
cancer expected for a pathogenic BRCA1 variant (current odds for causality of 8.50x10
-16 
based on 
segregation and pathology information, ENIGMA unpublished data), expresses mostly ∆9,10 transcripts, 
a significant proportion of out-of-frame ∆9 transcripts, and very few FL transcripts (14), strongly pointing 
to BRCA1
p.Gly183_Lys223del
 as a protein with tumor suppressor function. As far as we know, the only cancer 
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predisposition gene for which a similar alternative splicing rescue model has been proposed is the tumor 
suppressor adenomatous poliposis coli (APC) gene, albeit in this case loss of function variants in the 
alternatively spliced region of APC exon 9 are not associated with lack of risk, but with a milder 
phenotype, termed attenuated familial adenomatous polyposis(15).  
The BRCA1∆9,10 rescue model highlights the often neglected relevance of naturally occurring alternative 
splicing in the clinical arena, and has obvious implications for variant classification algorithms. The 
ENIGMA consortium has developed and documented criteria for the 5-tier classification of BRCA1/2 
genetic variants based on qualitative and quantitative information (http://www.enigmaconsortium.org/). 
According to these rules, and consistent with those proposed by InSiGHT for Mismatch Repair gene 
variants (1), BRCA1/2 variants considered extremely likely to alter splicing based on position (typically 
IVS±1 or IVS±2) were initially all considered Class-4 (likely pathogenic) if untested for splicing 
alterations. However, the findings presented in this study have been pivotal to support amendment to 
these classification criteria, specifying need for particular caution in interpreting variants in instances 
where ∆9,10 (or other known naturally occurring in-frame alternative splicing events) might rescue gene 
functionality (see Supplemental Table 3). Hence, we also recommend caution in interpreting coding 
sequence variants that lead to premature termination codons in BRCA1 exons 9 and 10. This conservative 
stance is consistent with recent American College of Medical Genetics (ACMG) guidelines (16), which 
recommend considering the presence of alternative gene transcripts, understanding which are biologically 
relevant, and in which tissues the products are expressed. Thus, caution should be exercised when 
interpreting the impact of truncating variants confined to only a subset of transcripts, given the presence 
of other protein isoforms.  
 
Of note, our results have additional implications unrelated to alternative splicing. More precisely, our 
study suggests that BRCA1 tumor suppressor activity tolerates a substantial reduction in expression level 
in vivo.  Indeed, results shown in Figure 4 indicate that a BRCA1 allele producing as much as ≈70-80% of 
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transcript encoding tumor suppressor deficient protein (as measured in blood-related samples) may not 
necessarily confer high-risk of developing cancer. This observation supports the conservative viewpoint 
of the ENIGMA consortium that, in the absence of other information, a variant can be considered 
pathogenic due to an effect on mRNA integrity if it only produces transcripts carrying a premature stop 
codon or an in-frame deletion disrupting known functional domain(s), as determined by semi-quantitative 
or quantitative methods.  
 
In brief, there are several broad messages arising from the present study. Our results confirm that mRNA 
and genetic studies are warranted to inform the clinical significance of sequence alterations at the highly 
conserved intronic dinucleotides of splice donor and acceptor sites, and highlight the need to consider 
both variant haplotype and alternative splicing events in the design and interpretation of assays assessing 
the functional consequences of variants of uncertain clinical significance. We have also shown that 
comprehensive understanding of alternative splicing, paired with clinical genetic studies, is critical to 
understand the clinical consequences of complex splicing profiles observed for certain spliceogenic 
variants. Lastly, we provide a baseline hypothesis for future investigation and interpretation of other 
likely spliceogenic BRCA1/2 variants, a hypothesis that has implications for informing standards for 
generic variant classification guidelines. 
 
Materials and Methods 
1. Genotyping and Sample Sets 
We undertook screening of BRCA1 c.594-2A>C by direct genotyping, as part of the iCOGS experiment 
detailed elsewhere (17, 18). This study included genotype and pathology results from breast cancer cases 
and controls participating in the Breast Cancer Association Consortium (BCAC; 
http://apps.ccge.medschl.cam.ac.uk/consortia/bcac//), and from carriers of BRCA1 assumed pathogenic 
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variants participating in the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA; 
http://apps.ccge.medschl.cam.ac.uk/consortia/cimba//). In addition, via the Evidence-based Network for 
Investigating Germline Mutant Alleles (ENIGMA, http://enigmaconsortium.org/, (19)), we identified 
probands recruited through familial cancer clinics who were found to be positive for BRCA1 c.594-2A>C 
via clinical genetic testing. All study participants were enrolled into national or regional studies under 
ethically-approved protocols. 
Information was recorded for all variant carriers regarding cancer status, age at diagnosis/interview, 
breast tumor pathology (grade, and Estrogen Receptor (ER), Progesterone Receptor (PR), and Herceptin-
2 (HER2) status), and also pedigree and segregation information where available. For carriers identified 
though CIMBA and ENIGMA, the genotype for exonic variant c.641A>G (p.Asp214Gly) was sought 
from the original clinical testing report.  
The BCAC dataset included 53,354 breast cancer cases and 49,720 controls and documented age at 
diagnosis/interview from 45 studies, detailed in (17).  The denominator reduced to 24,605 cases and 
25,836 controls when including only invasive breast cancer cases and controls from the 11 studies with at 
least one observation (Supplementary Table 1). These 11 studies included only individuals of European 
ancestry, and four (MCBS, MBCCSG, KARBAC, OFBCR) had undergone testing for germline BRCA1/2 
pathogenic variants (4% - 100% of samples, depending on the BCAC study), including two of four 
studies which sampled cases on the basis of reported family history or presence of bilateral disease.  
The CIMBA dataset included 11,105 female BRCA1 pathogenic variant carriers aged ≥ 18 y from 46 
studies in CIMBA recruited through cancer genetics clinics. There were 4,845 females without report of 
cancer, 4,713 breast cancer cases, 933 ovarian cancer cases, and 614 individuals reporting both breast and 
ovarian cancer. 
By contact with submitters and examination of clinical information, it was established that 11 of the 15 
CIMBA probands overlapped with individuals included in the ENIGMA dataset, and one of proband was 
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also a participant in BCAC site (Supplementary Table 2). Only non-overlapping data was included in 
multifactorial likelihood analysis.  
 
2. Statistical methods: 
We evaluated the effect of the BRCA1 c.594-2A>C variant on breast cancer risk in BCAC, using logistic 
regression models with adjustment for censoring age and population structure, based on six principal 
components which defined any residual population sub-structure. Censoring age was defined as age at 
breast cancer diagnosis, or age at last interview/follow-up. Only case-control studies in which the variant 
was observed at least once were included in the analysis.  
In order to place case-control data into the same likelihood ratio (LR) framework as the other lines of 
evidence used for multifactorial likelihood analysis (20, 21), we compared the likelihood of the 
distribution of BRCA1 c.594-2A>C variant carriers among cases and controls under the hypothesis that 
the variant has the same age specific relative risks as the “average” pathogenic BRCA1 mutation 
compared to that under the hypothesis that it is not associated with any increased breast cancer risk. 
Specifically, we used the age at diagnosis of cases and age at interview for controls together with the 
relative risks of breast cancer estimated from case series unselected for family history (6) to calculate the 
probability that each individual carrying  BRCA1 c.594-2A>C in the sample is a BRCA1 pathogenic 
variant carrier given their affected status and age. Under the hypothesis that BRCA1 c.594-2A>C is a 
benign variant and does not confer increased breast cancer risk, we calculated the probability of the 
distribution of cases and controls among BRCA1 c.594-2A>C carriers as a simple binomial probability 
with p=proportion of cases in the sample. These two likelihoods were then compared to derive the 
appropriate LR.  
Bayes scores for segregation were derived as described previously (22), and pathology LRs were applied 
as indicated in Spurdle et al (23).  The segregation scores, pathology LRs and case-control LRs are 
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mutually independent and were combined to derive a combined odds for causality as described previously 
(20). 
We used the program Phase 2.0 (24) to estimate the most likely haplotypes of the BCAC cases and 
controls based on 29 variants in the region within and surrounding the BRCA1 locus, in order to examine 
if all c.594-2A>C variant carriers were observed on the same haplotypic background. Variants used for 
phasing were those submitted by ENIGMA for inclusion on the iCOGS chip design, the most common of 
which were rs8176258, rs1799967, rs1799950, rs4986852, and rs1799966. 
 
3. mRNA Analysis methods:  
3.1. Nomenclature. We use as reference sequences to describe BRCA1 genetic variants the GenBank 
reference sequences U14680.1 (cDNA) and NC_000017.11 (genomic). When referring to BRCA1 exons, 
we use exon numbering according to U14680.1. To characterize the BRCA1 alternative splicing landscape 
in c.[594-2A>C; 641A>G] carriers (sometimes referred throughout the text as variant allele carriers), we 
performed different RNA splicing analyses at the immediate vicinity of BRCA1 exon 10 (defined as the 
gene region spanning exons 8 to 11). Since our methodology do not allow analysis of complete transcripts 
(from 5’-end to poly(A) tail), we refer throughout the text to alternative splicing event containing 
transcripts, or alternative splicing events, rather than to alternative splicing transcripts or RNA isoforms 
(7) . For the very same reason, full-length (FL) refers throughout the text to BRCA1 exons 9- and 10-
containing transcripts (transcripts containing the exons9/10 junction defined in the GenBank reference 
sequenceU14680.1), and not necessarily to the complete 5711nt mRNA described in U14680.1. We have 
designated alternative splicing events by combining U14680.1 exon numbering with the following 
symbols: ∆ (exon skipping), ▼ (intron retention), p (proximal, or 5'), and q (distal, or 3'). 3.2 RNA 
analysis of human samples. Up to seven contributing laboratories (sites 1 to 7) performed RNA splicing 
analyses with various methodologies, including fluorescent RT-PCR followed by capillary 
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electrophoresis, real-time quantitative PCR (qPCR), digital PCR (dPCR), Sanger sequencing, and 
RNAseq (see Supplemental Methods for further details). Experiments were performed in RNAs extracted 
from lymphoblastoid cell lines (LCLs), short-term (3-6 days) cultured Leukocytes (LEU), or fresh 
peripheral blood. RNAs were derived from 8 individual c.[594-2A>C; 641A>G] carriers (hereafter 
referred as Carriers 1 to 8) identified in four unrelated families from Australia (Carrier 1, LCL), Germany 
(Carrier 2, LCL), The Netherlands (Carriers 3 to 7, LEUs), and France (Carrier 8, peripheral blood), and 
healthy controls. We conducted several experiments designed to characterize the BRCA1 alternative 
splicing landscape observed in variant carriers. We used as quantitative description the splicing fraction 
(SF), defined here as the contribution of individual alternative splicing events to the overall BRCA1 
expression level (expressed as a percentage). As proxies for overall expression level, we used the Σ of all 
peak areas detected (capillary electrophoresis), or the signal obtained with a TaqMan assay recognizing 
the BRCA1 exons 23-24 junction (dPCR). The latter was selected since both BRCA1 exons 23 and 24 are 
likely constitutive exons (7). Note that SF is a relative measure between signals arising from the same 
locus (in this case BRCA1), so that it is neither directly related to the actual expression level on individual 
splicing events, nor with the overall expression level from that locus. It is formally possible that 
increments in the SF of one particular alternative splicing event correlate with actual reductions in the 
expression level of that splicing event. For that reason, we determine the absolute expression level of 
individual alternative splicing events by qPCR with standard curves (see supplemental methods for 
further details), and we performed relative expression analyses by dPCR, using as a reference a TaqMan 
assay recognizing the BRCA2 exons 26-27 junction. When indicated, we used as a positive control RNA 
extracted from LCLs carrying the BRCA1 variant c.591C>T [p.= (Cys197Cys)], known to increase ∆9
SF
 
and ∆9,10
SF
(14). Many experiments were performed in parallel with cultured cells treated/untreated with 
a nonsense mediated mRNA decay pathway (NMD) inhibitor, either Puromycin (Puro+/- experiments), or 
Cycloheximide (Cyclo+/- experiments). RNA from Carrier 8 was directly extracted from fresh peripheral 
blood. Biallelic expression was assessed by alternative splicing eventspecific RT-PCR followed by 
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Sanger sequencing through rs1060915 (an informative exonic SNP located at BRCA1 exon 13), using 
primers and protocols previously described (14). In addition, we searched for BRCA1 tissue specific 
alternative splicing landscape in clinically relevant samples by comparing RNAs extracted from healthy 
control fresh peripheral blood, a pool of 10 healthy breast tissues (enriched normal epithelial areas 
selected by a pathologist) adjacent to breast tumor samples, and commercial RNAs from healthy breast 
and ovarian human tissues. Experiments were performed by capillary electrophoresis of RT-PCR 
products, and by dPCR. Depending on the contributing laboratories, different RNA isolation and cDNA 
synthesis approaches were used (see Supplemental Methods for further details).     
3.3. Minigene Splicing Assays. To dissect the contribution of the individual BRCA1 variants c.594-2A>C 
and c.641A>G to the splicing alteration observed in c.[594-2A>C; 641A>G] carriers, we performed  
splicing assays with 2 different types of reported minigenes: pCAS2-BRCA1-Exon10 and pB1 (a 
minigene spanning BRCA1 exons 8 to 12). S e Supplemental Methods and Figure 3 for further details.     
3.4. RNA interference experiments. To identify splicing regulatory proteins involved in BRCA1 exon 10 
splicing, we performed a series of RNA interference experiments knocking down diverse splicing 
regulatory factors (hnRNPA1, Tra2β, SF2/ASF, and SC35). Experiments were performed in the breast 
cancer cell line MDAMD231 (see Supplemental Methods for further details).  
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Legends to Figures  
Figure 1. Capillary Electrophoresis analyses of BRCA1alternative splicing landscape  in LCLs from 
one BRCA1c.[594-2A>C; 641A>G] carrier (Carrier 1) and 10 Controls. Panel A shows representative 
examples of capillary electrophoresis analysis of RT-PCR products generated with the E8.1-E11p assay in 
LCLs treated (Puro+) or untreated (Puro-) with the nonsense mediated decay inhibitor puromycin. The 
fluorescence intensity of each peak (Y-axis) is expressed in arbritary units (AU). The analyses detected 
the full-length transcript (FL), and up to four alternative splicing events, two in-frame (∆9,10 and ▼10p) 
and two out-of-frame (∆9, and ∆10). In these particular examples, ▼10p transcripts are detected only in 
Carrier 1, but we have detected ▼10p transcripts in Controls, as summarized in panel B. The presence of 
▼10p in Controls has been further confirmedby RNAseq (see Supp. Figure 3).The boxplots in Panel B 
(displaying low, Q1, median, Q3, and high values)  show the splicing fraction (SF) of in-frame transcripts 
(∆9,10,  FL and ▼10p) observed in Carrier 1 (3 technical replicas) and 10 Controls. SF expressed as the 
% of the corresponding peak area to the Σ of all five peak areas detected by capillary electrophoresis. This 
particular experiment was performed with the E8.2-E11q.2 assay. Note that the ▼10p
SF
  is rather minor 
(<1%) regardless of the LCL tested. The FL
SF
 was much lower in Carrier 1 than in Control samples. The 
boxplots in Panel C (displaying low, Q1, median, Q3, and high values) show the SF of out-of-frame 
transcripts (∆9 and ∆10) observed in Carrier 1 (3 technical replicates) and 10 Controls. The relative 
contribution of ∆10 to the overall signal was much higher in Carrier 1 than in Control samples. Normal 
outliers (>1.5 interquartile range, IQR) display small circles. (** represents P≤0.01) (*** represents 
P≤0.001) (ns=non-significant).  
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Figure 2.  Quantification of major in-frame transcripts ∆9,10 and full-length (FL) in LCLs from 
one BRCA1c.[594-2A>C; 641A>G] carrier (Carrier 1) and Controls. Experiments were performed in 
LCLs treated with Puromycin (Puro+). Panel A displays ∆9,10
SF
 and FL
SF
, estimated as the ratio between 
the GADPH normalized absolute numbers of ∆9,10 (or FL) molecules and absolute number of all BRCA1 
transcripts, as determined by qPCR analysis performed with standard curves (see Supplemental Methods 
and Supplemental Figure 4). Standard deviation of 3 independent measures is shown. Panel B displays 
dPCR data measuring ∆9,10
SF
 and FL (inclusion of exons 9 and 10)
SF
, using exon23-24 junction as a 
proxy for overall BRCA1 expression level. The precision of each measure (as determined by the 
QuantStudio 3D Analysis Cloud Software) is indicated. Two technical replicates of Carrier 1 are shown.  
We included as positive control a LCL carrying the BRCA1 c.591C>T variant, known to increase ∆9,10
SF
. 
The ∆9,10
SF 
in Carrier 1 was higher than in Controls (24% in two technical replicates of Carrier 1 vs. an 
average of 17% in 7 control samples, Mann-Whitney U test; p=0.028 for difference between groups), but 
a 50% reduction of FL
SF 
(50% in two technical replicas of Carrier 1 vs. an average of 94% in 6 control 
samples, Mann-Whitney U test; p=0.036 for difference between groups). 
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Figure 3.  Analysis of BRCA1 c.594-2A>C and c.641A>G variants with splicing reporter minigene 
assays. The figure shows schematic non-scale representations of the splicing reporter minigenes pCAS2-
BRCA1-exon10 (panel A) and pB1 (panel B) used for splicing assays. Minigenes were constructed as 
described under Supplemental Methods. PCMV indicates the cytomegalovirus promoter, boxes represent 
exons and lines in between indicate introns. BRCA1 sequences are highlighted in black. Arrows represent 
primers used in RT-PCR reactions. With the exception of pB1 BRCA1 intron 11 (402 nt-long full-length 
IVS11), minigenes harbor partial segments of BRCA1 introns. For comparative purposes, the size in 
nucleotides of each segment is shown together with the size corresponding to the endogenous full-length 
BRCA1 introns shown in brackets. As indicated, pB1 carries an additional cytosine (+3insC) in exon 8 to 
keep the ORF with α-globin exon 1 (Raponi et al., 2012).  Splicing assays were performed by analyzing 
the splicing pattern of WT and mutant minigenes (c.594-2A>C, c.641A>G, and c.[594-2A>C; 641A>G]) 
transiently expressed in human cells (HeLa, COS-7, MCF7, HBL100 or IGROV-1) as described under 
Supplemental Methods. The images show RT-PCR products separated in ethidium bromide-stained 
agarose gels. FL, full-length; ∆9, exon 9 skipping; ∆10, exon 10 skipping; ∆9,10, skipping of both exons 
9 and 10;  *, retention of 21 intronic nucleotides immediately upstream exon 10 (▼10p). One can note 
that: (i) the relative level of alternatively spliced pB1(WT) transcripts is higher in IGROV-1 than in 
HeLa, MCF-7, or HBL100 cells, and (ii) the predominant alternative splicing event of pB1(WT) in these 
cell lines is ∆10, whereas that of endogenous wild-type BRCA1 in blood related samples is  ∆9,10 (Figure 
4 and Supplemental Figures 1 and 2).   
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Figure 4. Combined genetic and splicing analyses of BRCA1 c.[594-2A>C; 641A>G] and BRCA1 
c.591C>T supports a BRCA1∆9,10 rescue model with far-reaching clinical implications. Panel A 
(top) shows the splicing fraction (SF) of five alternative splicing events detected by capillary 
electrophoresis analysis of RT-PCR products generated with the E8.2-E11q.2 assay (Puro+ experiments, 
36 cycle PCRs, see Figure 1 and Supplemental Figure 1 for further details). As shown, this description of 
the BRCA1 alternative splicing landscape in the vicinity of exon 10 is different in healthy control samples, 
c.[594-2A>C; 641A>G] carriers, and c.591C>T carriers. Yet, we show in the present study that none of 
these 3 BRCA1 splicing landscapes is associated with high risk of developing BRCA1 related cancers. The 
chart displays SFs that, in carriers, represent a combined signal from the variant allele and the 
accompanying WT allele. Panel A (bottom). Deduced per allele SFs are shown. Assuming that SFs 
arising from the accompanying WT allele equal to the average SFs observed in 10 Control samples (as 
shown in the central chart bar), we deconvoluted the SFs corresponding to c.[594-2G; c.641G]  (left chart 
bar) and c.591T  (right chart bar) alleles. Panel B. The cartoon represents the relative per allele (100% 
equals to the overall expression level arising from one individual allele) and per cell (100% equals to the 
overall expression arising from a diploid genome) expression (BRCA1 exons 7 to 11) in a c.[594-2G; 
c.641G] carrier, inferred from capillary EP analyses shown in Panel A. For simplicity, only FL and ∆9,10 
transcripts are shown, albeit ∆9 and ▼10p transcripts account for ≈5% of the per cell expression. 
Truncating (out-of-frame) events are highlighted with a red cross.  The analysis suggests that expressing 
up to ≈35% of BRCA1 PTC-NMD transcripts (per diploid genome) is not associated with high-risk of 
developing cancer. The analysis suggests as well that a BRCA1 allele expressing up to ≈70% (per allele) 
BRCA1 PTC-NMD transcripts is not associated with high-risk of developing cancer (a relevant finding in 
the context of the two-hit model). Panel C. The cartoon represents the relative per allele (100% equals to 
the overall expression level arising from one individual allele) and per cell (100% equals to the overall 
expression arising from a diploid genome) expression (BRCA1 exons 7 to 11) in a c.591C>T carrier, 
inferred from capillary EP analyses shown in Panel A. For simplicity, only FL, ∆9,10 and ∆9 (variant 
allele) are shown, albeit ∆9 (wt allele), ∆10 (wt and variant allele), and ▼10p (wt and variant allele) 
transcripts account for ≈5% of the per cell expression. The data strongly suggests that BRCA1∆9,10 
transcripts, representing up to 51% (per diploid genome) and up to 71% (per allele) of the overall BRCA1 
expression code for a BRCA1 protein with tumor suppressor activity. The model displayed in this figure 
is intended to illustrate the most relevant findings of our study. Yet, some limitations should be 
highlighted. First, the model assumes (based on 36-cycle PCR capillary EP data) that ∆9,10
SF 
in Controls 
and c.[594-2A>C; 641A>G] carriers is ≈29%, while other experiments suggests that the actual value is 
probably lower in both instances (Figure 2, Supplemental Figure 2), albeit slightly increased in Carriers 
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vs. Controls. The model has been elaborated with data obtained in LCLs, not in clinically relevant tissues 
such as breast or ovarian. 
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Abbreviations 
 
Cyclo-  Cycloheximide absent 
Cyclo+ Cycoeximide present 
dPCR digital PCR 
qPCR quantitative PCR 
FL  full-length 
LCL  lymphoblastoid cell line 
LEU  leukocyte 
NMD  nonsense mediated decay  
PTC  premature termination codon 
Puro-  Puromycin absent 
Puro+  Puromycin present 
qPCR quantitative PCR 
RNAseq high-throughput RNA sequencing 
RT       reverse transcription 
SF  splicing fraction 
siRNA small interference RNA 
WT  wildtype 
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Figure 1. Capillary Electrophoresis analyses of BRCA1alternative splicing landscape  in LCLs from one 
BRCA1c.[594-2A>C; 641A>G] carrier (Carrier 1) and 10 Controls. Panel A shows representative examples of 
capillary electrophoresis analysis of RT-PCR products generated with the E8.1-E11p assay in LCLs treated 
(Puro+) or untreated (Puro-) with the nonsense mediated decay inhibitor puromycin. The fluorescence 
intensity of each peak (Y-axis) is expressed in arbritary units (AU). The analyses detected the full-length 
transcript (FL), and up to four alternative splicing events, two in-frame (D9,10 and ▼10p) and two out-of-
frame (D9, and D10). In these particular examples, ▼10p transcripts are detected only in Carrier 1, but we 
have detected ▼10p transcripts in Controls, as summarized in panel B. The presence of ▼10p in Controls 
has been further confirmedby RNAseq (see Supp. Figure 3).The boxplots in Panel B (displaying low, Q1, 
median, Q3, and high values)  show the splicing fraction (SF) of in-frame transcripts (D9,10,  FL and ▼10p) 
observed in Carrier 1 (3 technical replicas) and 10 Controls. SF expressed as the % of the corresponding 
peak area to the Σ of all five peak areas detected by capillary electrophoresis. This particular experiment 
was performed with the E8.2-E11q.2 assay. Note that the ▼10pSF  is rather minor (<1%) regardless of the 
LCL tested. The FLSF was much lower in Carrier 1 than in Control samples. The boxplots in Panel C 
(displaying low, Q1, median, Q3, and high values) show the SF of out-of-frame transcripts (D9 and D10) 
observed in Carrier 1 (3 technical replicates) and 10 Controls. The relative contribution of D10 to the overall 
signal was much higher in Carrier 1 than in Control samples. Normal outliers (>1.5 interquartile range, IQR) 
display small circles. (** represents P≤0.01) (*** represents P≤0.001) (ns=non-significant).  
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Figure 2.  Quantification of major in-frame transcripts D9,10 and full-length (FL) in LCLs from one 
BRCA1c.[594-2A>C; 641A>G] carrier (Carrier 1) and Controls. Experiments were performed in LCLs treated 
with Puromycin (Puro+). Panel A displays D9,10SF and FLSF, estimated as the ratio between the GADPH 
normalized absolute numbers of D9,10 (or FL) molecules and absolute number of all BRCA1 transcripts, as 
determined by qPCR analysis performed with standard curves (see Supplemental Methods and Supplemental 
Figure 4). Standard deviation of 3 independent measures is shown. Panel B displays dPCR data measuring 
D9,10SF and FL (inclusion of exons 9 and 10)SF, using exon23-24 junction as a proxy for overall BRCA1 
expression level. The precision of each measure (as determined by the QuantStudio 3D Analysis Cloud 
Software) is indicated. Two technical replicates of Carrier 1 are shown.  We included as positive control a 
LCL carrying the BRCA1 c.591C>T variant, known to increase D9,10SF. The D9,10SF in Carrier 1 was higher 
than in Controls (24% in two technical replicates of Carrier 1 vs. an average of 17% in 7 control samples, 
Mann-Whitney U test; p=0.028 for difference between groups), but a 50% reduction of FLSF (50% in two 
technical replicas of Carrier 1 vs. an average of 94% in 6 control samples, Mann-Whitney U test; p=0.036 
for difference between groups).  
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Figure 3.  Analysis of BRCA1 c.594-2A>C and c.641A>G variants with splicing reporter minigene assays. The 
figure shows schematic non-scale representations of the splicing reporter minigenes pCAS2-BRCA1-exon10 
(panel A) and pB1 (panel B) used for splicing assays. Minigenes were constructed as described under 
Supplemental Methods. PCMV indicates the cytomegalovirus promoter, boxes represent exons and lines in 
between indicate introns. BRCA1 sequences are highlighted in black. Arrows represent primers used in RT-
PCR reactions. With the exception of pB1 BRCA1 intron 11 (402 nt-long full-length IVS11), minigenes harbor 
partial segments of BRCA1 introns. For comparative purposes, the size in nucleotides of each segment is 
shown together with the size corresponding to the endogenous full-length BRCA1 introns shown in brackets. 
As indicated, pB1 carries an additional cytosine (+3insC) in exon 8 to keep the ORF with a-globin exon 1 
(Raponi et al., 2012).  Splicing assays were performed by analyzing the splicing pattern of WT and mutant 
minigenes (c.594-2A>C, c.641A>G, and c.[594-2A>C; 641A>G]) transiently expressed in human cells 
(HeLa, COS-7, MCF7, HBL100 or IGROV-1) as described under Supplemental Methods. The images show RT-
PCR products separated in ethidium bromide-stained agarose gels. FL, full-length; D9, exon 9 skipping; 
D10, exon 10 skipping; D9,10, skipping of both exons 9 and 10;  *, retention of 21 intronic nucleotides 
immediately upstream exon 10 (▼10p). One can note that: (i) the relative level of alternatively spliced 
pB1(WT) transcripts is higher in IGROV-1 than in HeLa, MCF-7, or HBL100 cells, and (ii) the predominant 
alternative splicing event of pB1(WT) in these cell lines is D10, whereas that of endogenous wild-type 
BRCA1 in blood related samples is  D9,10 (Figure 4 and Supplemental Figures 1 and 2).    
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Figure 4. Combined genetic and splicing analyses of B CA1 c.[594-2A>C; 641A>G] and BRCA1 c.591C>T 
supports a BRCA1D9,10 rescue model with far-reaching clinical implications. Panel A (top) shows the splicing 
fraction (SF) of five alternative splicing events detected by capillary electrophoresis analysis of RT-PCR 
products generated with the E8.2-E11q.2 assay (Puro+ experiments, 36 cycle PCRs, see Figure 1 and 
Supplemental Figure 1 for further details). As shown, this description of the BRCA1 alternative splicing 
landscape in the vicinity of exon 10 is different in healthy control samples, c.[594-2A>C; 641A>G] carriers, 
and c.591C>T carriers. Yet, we show in the present study that none of these 3 BRCA1 splicing landscapes is 
associated with high risk of developing BRCA1 related cancers. The chart displays SFs that, in carriers, 
represent a combined signal from the variant allele and the accompanying WT allele. Panel A (bottom). 
Deduced per allele SFs are shown. Assuming that SFs arising from the accompanying WT allele equal to the 
average SFs observed in 10 Control samples (as shown in the central chart bar), we deconvoluted the SFs 
corresponding to c.[594-2G; c.641G]  (left chart bar) and c.591T  (right chart bar) alleles. Panel B. The 
cartoon represents the relative per allele (100% equals to the overall expression level arising from one 
individual allele) and per cell (100% equals to the overall expression arising from a diploid genome) 
expression (BRCA1 exons 7 to 11) in a c.[594-2G; c.641G] carrier, inferred from capillary EP analyses 
shown in Panel A. For simplicity, only FL and D9,10 transcripts are shown, albeit D9 and ▼10p transcripts 
account for ≈5% of the per cell expression. Truncating (out-of-frame) events are highlighted with a red 
cross.  The analysis suggests that expressing up to ≈35% of BRCA1 PTC-NMD transcripts (per diploid 
genome) is not associated with high-risk of developing cancer. The analysis suggests as well that a BRCA1 
allele expressing up to ≈70% (per allele) BRCA1 PTC-NMD transcripts is not associated with high-risk of 
developing cancer (a relevant finding in the context of the two-hit model). Panel C. The cartoon represents 
the relative per allele (100% equals to the overall expression level arising from one individual allele) and per 
cell (100% equals to the overall expression arising from a diploid genome) expression (BRCA1 exons 7 to 
11) in a c.591C>T carrier, inferred from capillary EP analyses shown in Panel A. For simplicity, only FL, 
D9,10 and D9 (variant allele) are shown, albeit D9 (wt allele), D10 (wt and variant allele), and ▼10p (wt 
and variant allele) transcripts account for ≈5% of the per cell expression. The data strongly suggests that 
BRCA1D9,10 transcripts, representing up to 51% (per diploid genome) and up to 71% (per allele) of the 
overall BRCA1 expression code for a BRCA1 protein with tumor suppressor activity. The model displayed in 
this figure is intended to illustrate the most relevant findings of our study. Yet, some limitations should be 
highlighted. F  
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